. 2018 Jan; 118(1):9-16.
doi: 10.1038/bjc.2017.434.

Mechanisms of resistance to immune checkpoint inhibitors

Russell W Jenkins 1 David A Barbie 2 Keith T Flaherty 1 
  • PMID: 29319049
  •     84 References
  •     370 citations


Immune checkpoint inhibitors (ICI) targeting CTLA-4 and the PD-1/PD-L1 axis have shown unprecedented clinical activity in several types of cancer and are rapidly transforming the practice of medical oncology. Whereas cytotoxic chemotherapy and small molecule inhibitors ('targeted therapies') largely act on cancer cells directly, immune checkpoint inhibitors reinvigorate anti-tumour immune responses by disrupting co-inhibitory T-cell signalling. While resistance routinely develops in patients treated with conventional cancer therapies and targeted therapies, durable responses suggestive of long-lasting immunologic memory are commonly seen in large subsets of patients treated with ICI. However, initial response appears to be a binary event, with most non-responders to single-agent ICI therapy progressing at a rate consistent with the natural history of disease. In addition, late relapses are now emerging with longer follow-up of clinical trial populations, suggesting the emergence of acquired resistance. As robust biomarkers to predict clinical response and/or resistance remain elusive, the mechanisms underlying innate (primary) and acquired (secondary) resistance are largely inferred from pre-clinical studies and correlative clinical data. Improved understanding of molecular and immunologic mechanisms of ICI response (and resistance) may not only identify novel predictive and/or prognostic biomarkers, but also ultimately guide optimal combination/sequencing of ICI therapy in the clinic. Here we review the emerging clinical and pre-clinical data identifying novel mechanisms of innate and acquired resistance to immune checkpoint inhibition.

Augmenting antitumor immune responses with epigenetic modifying agents.
Erika Héninger, Timothy E G Krueger, Joshua M Lang.
Front Immunol, 2015 Feb 24; 6. PMID: 25699047    Free PMC article.
Highly Cited. Review.
Progenitor and terminal subsets of CD8+ T cells cooperate to contain chronic viral infection.
Michael A Paley, Daniela C Kroy, +8 authors, E John Wherry.
Science, 2012 Dec 01; 338(6111). PMID: 23197535    Free PMC article.
Highly Cited.
Targeting natural killer cells in cancer immunotherapy.
Camille Guillerey, Nicholas D Huntington, Mark J Smyth.
Nat Immunol, 2016 Aug 20; 17(9). PMID: 27540992
Highly Cited. Review.
"In vitro" 3D models of tumor-immune system interaction.
Christian Hirt, Adam Papadimitropoulos, +6 authors, Giulio C Spagnoli.
Adv Drug Deliv Rev, 2014 May 14; 79-80. PMID: 24819215
Tumor immune profiling predicts response to anti-PD-1 therapy in human melanoma.
Adil I Daud, Kimberly Loo, +15 authors, Michael D Rosenblum.
J Clin Invest, 2016 Aug 16; 126(9). PMID: 27525433    Free PMC article.
Highly Cited.
Immune checkpoint blockade: a common denominator approach to cancer therapy.
Suzanne L Topalian, Charles G Drake, Drew M Pardoll.
Cancer Cell, 2015 Apr 11; 27(4). PMID: 25858804    Free PMC article.
Highly Cited. Review.
Evolution of Neoantigen Landscape during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.
Valsamo Anagnostou, Kellie N Smith, +26 authors, Victor E Velculescu.
Cancer Discov, 2016 Dec 30; 7(3). PMID: 28031159    Free PMC article.
Highly Cited.
An immunogenic personal neoantigen vaccine for patients with melanoma.
Patrick A Ott, Zhuting Hu, +37 authors, Catherine J Wu.
Nature, 2017 Jul 06; 547(7662). PMID: 28678778    Free PMC article.
Highly Cited.
Escape of human solid tumors from T-cell recognition: molecular mechanisms and functional significance.
F M Marincola, E M Jaffee, D J Hicklin, S Ferrone.
Adv Immunol, 1999 Dec 22; 74. PMID: 10605607
Highly Cited. Review.
Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses.
Katherine B Chiappinelli, Pamela L Strissel, +20 authors, Reiner Strick.
Cell, 2015 Sep 01; 162(5). PMID: 26317466    Free PMC article.
Highly Cited.
Analysis of Immune Signatures in Longitudinal Tumor Samples Yields Insight into Biomarkers of Response and Mechanisms of Resistance to Immune Checkpoint Blockade.
Pei-Ling Chen, Whijae Roh, +41 authors, Jennifer A Wargo.
Cancer Discov, 2016 Jun 16; 6(8). PMID: 27301722    Free PMC article.
Highly Cited.
Cancer Immunotherapy by Targeting IDO1/TDO and Their Downstream Effectors.
Michael Platten, Nikolaus von Knebel Doeberitz, +2 authors, Katharina Ochs.
Front Immunol, 2015 Jan 30; 5. PMID: 25628622    Free PMC article.
Highly Cited. Review.
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity.
Stefani Spranger, Riyue Bao, Thomas F Gajewski.
Nature, 2015 May 15; 523(7559). PMID: 25970248
Highly Cited.
Association of Pembrolizumab With Tumor Response and Survival Among Patients With Advanced Melanoma.
Antoni Ribas, Omid Hamid, +25 authors, Caroline Robert.
JAMA, 2016 Apr 20; 315(15). PMID: 27092830
Highly Cited.
Combination cancer immunotherapy and new immunomodulatory targets.
Kathleen M Mahoney, Paul D Rennert, Gordon J Freeman.
Nat Rev Drug Discov, 2015 Aug 01; 14(8). PMID: 26228759
Highly Cited. Review.
Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice.
Janet Lau, Jeanne Cheung, +17 authors, Maike Schmidt.
Nat Commun, 2017 Feb 22; 8. PMID: 28220772    Free PMC article.
Highly Cited.
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response.
Alexander C Huang, Michael A Postow, +31 authors, E John Wherry.
Nature, 2017 Apr 12; 545(7652). PMID: 28397821    Free PMC article.
Highly Cited.
Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.
Weiyi Peng, Jie Qing Chen, +41 authors, Patrick Hwu.
Cancer Discov, 2015 Dec 10; 6(2). PMID: 26645196    Free PMC article.
Highly Cited.
A Threshold Level of Intratumor CD8+ T-cell PD1 Expression Dictates Therapeutic Response to Anti-PD1.
Shin Foong Ngiow, Arabella Young, +4 authors, Mark J Smyth.
Cancer Res, 2015 Jul 26; 75(18). PMID: 26208901
Highly Cited.
Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors.
Daniela S Thommen, Jens Schreiner, +14 authors, Alfred Zippelius.
Cancer Immunol Res, 2015 Aug 09; 3(12). PMID: 26253731
Highly Cited.
Human memory T cells: generation, compartmentalization and homeostasis.
Donna L Farber, Naomi A Yudanin, Nicholas P Restifo.
Nat Rev Immunol, 2013 Dec 18; 14(1). PMID: 24336101    Free PMC article.
Highly Cited. Review.
A melanoma cell state distinction influences sensitivity to MAPK pathway inhibitors.
David J Konieczkowski, Cory M Johannessen, +14 authors, Levi A Garraway.
Cancer Discov, 2014 Apr 29; 4(7). PMID: 24771846    Free PMC article.
Highly Cited.
CXCR5(+) follicular cytotoxic T cells control viral infection in B cell follicles.
Yew Ann Leong, Yaping Chen, +34 authors, Di Yu.
Nat Immunol, 2016 Aug 04; 17(10). PMID: 27487330
Highly Cited.
Combination cancer immunotherapies tailored to the tumour microenvironment.
Mark J Smyth, Shin Foong Ngiow, Antoni Ribas, Michele W L Teng.
Nat Rev Clin Oncol, 2015 Nov 26; 13(3). PMID: 26598942
Highly Cited. Review.
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma.
Suzanne George, Diana Miao, +13 authors, Eliezer M Van Allen.
Immunity, 2017 Feb 24; 46(2). PMID: 28228279    Free PMC article.
Highly Cited.
Disruption of CXCR2-mediated MDSC tumor trafficking enhances anti-PD1 efficacy.
Steven L Highfill, Yongzhi Cui, +5 authors, Crystal L Mackall.
Sci Transl Med, 2014 May 23; 6(237). PMID: 24848257    Free PMC article.
Highly Cited.
STK11/LKB1 Deficiency Promotes Neutrophil Recruitment and Proinflammatory Cytokine Production to Suppress T-cell Activity in the Lung Tumor Microenvironment.
Shohei Koyama, Esra A Akbay, +30 authors, Kwok-Kin Wong.
Cancer Res, 2016 Feb 03; 76(5). PMID: 26833127    Free PMC article.
Highly Cited.
Mouse models in oncoimmunology.
Laurence Zitvogel, Jonathan M Pitt, +2 authors, Guido Kroemer.
Nat Rev Cancer, 2016 Nov 04; 16(12). PMID: 27687979
Highly Cited. Review.
Nivolumab and ipilimumab versus ipilimumab in untreated melanoma.
Michael A Postow, Jason Chesney, +18 authors, F Stephen Hodi.
N Engl J Med, 2015 Apr 22; 372(21). PMID: 25891304    Free PMC article.
Highly Cited.
Shaping and reshaping CD8+ T-cell memory.
John T Harty, Vladimir P Badovinac.
Nat Rev Immunol, 2008 Jan 26; 8(2). PMID: 18219309
Highly Cited. Review.
In vivo imaging reveals a tumor-associated macrophage-mediated resistance pathway in anti-PD-1 therapy.
Sean P Arlauckas, Christopher S Garris, +9 authors, Mikael J Pittet.
Sci Transl Med, 2017 May 12; 9(389). PMID: 28490665    Free PMC article.
Highly Cited.
Mismatch repair deficiency predicts response of solid tumors to PD-1 blockade.
Dung T Le, Jennifer N Durham, +43 authors, Luis A Diaz.
Science, 2017 Jun 10; 357(6349). PMID: 28596308    Free PMC article.
Highly Cited.
Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade.
Nicholas McGranahan, Andrew J S Furness, +33 authors, Charles Swanton.
Science, 2016 Mar 05; 351(6280). PMID: 26940869    Free PMC article.
Highly Cited.
Distinct Cellular Mechanisms Underlie Anti-CTLA-4 and Anti-PD-1 Checkpoint Blockade.
Spencer C Wei, Jacob H Levine, +8 authors, James P Allison.
Cell, 2017 Aug 15; 170(6). PMID: 28803728    Free PMC article.
Highly Cited.
Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma.
Dirk Schadendorf, F Stephen Hodi, +7 authors, Jedd D Wolchok.
J Clin Oncol, 2015 Feb 11; 33(17). PMID: 25667295    Free PMC article.
Highly Cited.
PD-1 blockade with nivolumab in relapsed or refractory Hodgkin's lymphoma.
Stephen M Ansell, Alexander M Lesokhin, +16 authors, Philippe Armand.
N Engl J Med, 2014 Dec 09; 372(4). PMID: 25482239    Free PMC article.
Highly Cited.
Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer.
Ugur Sahin, Evelyna Derhovanessian, +47 authors, Özlem Türeci.
Nature, 2017 Jul 06; 547(7662). PMID: 28678784
Highly Cited.
In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target.
Robert T Manguso, Hans W Pope, +16 authors, W Nicholas Haining.
Nature, 2017 Jul 21; 547(7664). PMID: 28723893    Free PMC article.
Highly Cited.
Epigenetic stability of exhausted T cells limits durability of reinvigoration by PD-1 blockade.
Kristen E Pauken, Morgan A Sammons, +16 authors, E John Wherry.
Science, 2016 Oct 30; 354(6316). PMID: 27789795    Free PMC article.
Highly Cited.
Targeting Tim-3 and PD-1 pathways to reverse T cell exhaustion and restore anti-tumor immunity.
Kaori Sakuishi, Lionel Apetoh, +3 authors, Ana C Anderson.
J Exp Med, 2010 Sep 08; 207(10). PMID: 20819927    Free PMC article.
Highly Cited.
PD-1 Blockade Expands Intratumoral Memory T Cells.
Antoni Ribas, Daniel Sanghoon Shin, +14 authors, Begoña Comin-Anduix.
Cancer Immunol Res, 2016 Jan 21; 4(3). PMID: 26787823    Free PMC article.
Highly Cited.
The blockade of immune checkpoints in cancer immunotherapy.
Drew M Pardoll.
Nat Rev Cancer, 2012 Mar 23; 12(4). PMID: 22437870    Free PMC article.
Highly Cited. Review.
Molecular and genetic properties of tumors associated with local immune cytolytic activity.
Michael S Rooney, Sachet A Shukla, +2 authors, Nir Hacohen.
Cell, 2015 Jan 17; 160(1-2). PMID: 25594174    Free PMC article.
Highly Cited.
Rational combinations of immunotherapeutics that target discrete pathways.
Stefani Spranger, Thomas Gajewski.
J Immunother Cancer, 2013 Jan 01; 1. PMID: 24829752    Free PMC article.
A Relay Pathway between Arginine and Tryptophan Metabolism Confers Immunosuppressive Properties on Dendritic Cells.
Giada Mondanelli, Roberta Bianchi, +20 authors, Ursula Grohmann.
Immunity, 2017 Feb 19; 46(2). PMID: 28214225    Free PMC article.
Highly Cited.
Non-genomic and Immune Evolution of Melanoma Acquiring MAPKi Resistance.
Willy Hugo, Hubing Shi, +10 authors, Roger S Lo.
Cell, 2015 Sep 12; 162(6). PMID: 26359985    Free PMC article.
Highly Cited.
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy.
Dongjun Peng, Ilona Kryczek, +15 authors, Weiping Zou.
Nature, 2015 Oct 28; 527(7577). PMID: 26503055    Free PMC article.
Highly Cited.
IFN-γ is required for cytotoxic T cell-dependent cancer genome immunoediting.
Kazuyoshi Takeda, Masafumi Nakayama, +7 authors, Mark J Smyth.
Nat Commun, 2017 Feb 25; 8. PMID: 28233863    Free PMC article.
PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity.
Vikram R Juneja, Kathleen A McGuire, +5 authors, Arlene H Sharpe.
J Exp Med, 2017 Mar 18; 214(4). PMID: 28302645    Free PMC article.
Highly Cited.
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer.
Martin Reck, Delvys Rodríguez-Abreu, +16 authors, KEYNOTE-024 Investigators.
N Engl J Med, 2016 Oct 11; 375(19). PMID: 27718847
Highly Cited.
Innate and adaptive immune cells in the tumor microenvironment.
Thomas F Gajewski, Hans Schreiber, Yang-Xin Fu.
Nat Immunol, 2013 Sep 21; 14(10). PMID: 24048123    Free PMC article.
Highly Cited. Review.
Mutational heterogeneity in cancer and the search for new cancer-associated genes.
Michael S Lawrence, Petar Stojanov, +61 authors, Gad Getz.
Nature, 2013 Jun 19; 499(7457). PMID: 23770567    Free PMC article.
Highly Cited.
The epigenetic landscape of T cell exhaustion.
Debattama R Sen, James Kaminski, +16 authors, W Nicholas Haining.
Science, 2016 Oct 30; 354(6316). PMID: 27789799    Free PMC article.
Highly Cited.
T cell exclusion, immune privilege, and the tumor microenvironment.
Johanna A Joyce, Douglas T Fearon.
Science, 2015 Apr 04; 348(6230). PMID: 25838376
Highly Cited. Review.
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells.
KiBem Kim, Andrew D Skora, +8 authors, Shibin Zhou.
Proc Natl Acad Sci U S A, 2014 Jul 30; 111(32). PMID: 25071169    Free PMC article.
Highly Cited.
Up-regulation of PD-L1, IDO, and T(regs) in the melanoma tumor microenvironment is driven by CD8(+) T cells.
Stefani Spranger, Robbert M Spaapen, +4 authors, Thomas F Gajewski.
Sci Transl Med, 2013 Aug 30; 5(200). PMID: 23986400    Free PMC article.
Highly Cited.
Precision medicine for cancer with next-generation functional diagnostics.
Adam A Friedman, Anthony Letai, David E Fisher, Keith T Flaherty.
Nat Rev Cancer, 2015 Nov 06; 15(12). PMID: 26536825    Free PMC article.
Highly Cited. Review.
PD-1 and its ligands in tolerance and immunity.
Mary E Keir, Manish J Butte, Gordon J Freeman, Arlene H Sharpe.
Annu Rev Immunol, 2008 Jan 05; 26. PMID: 18173375
Highly Cited. Review.
T Cell Factor 1-Expressing Memory-like CD8(+) T Cells Sustain the Immune Response to Chronic Viral Infections.
Daniel T Utzschneider, Mélanie Charmoy, +11 authors, Werner Held.
Immunity, 2016 Aug 18; 45(2). PMID: 27533016
Highly Cited.
PD-L1 Studies Across Tumor Types, Its Differential Expression and Predictive Value in Patients Treated with Immune Checkpoint Inhibitors.
Harriet M Kluger, Christopher R Zito, +9 authors, Lucia B Jilaveanu.
Clin Cancer Res, 2017 Feb 23; 23(15). PMID: 28223273    Free PMC article.
Follicular CXCR5- expressing CD8(+) T cells curtail chronic viral infection.
Ran He, Shiyue Hou, +24 authors, Lilin Ye.
Nature, 2016 Aug 09; 537(7620). PMID: 27501245
Highly Cited.
DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.
David Roulois, Helen Loo Yau, +9 authors, Daniel D De Carvalho.
Cell, 2015 Sep 01; 162(5). PMID: 26317465    Free PMC article.
Highly Cited.
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma.
Eliezer M Van Allen, Diana Miao, +19 authors, Levi A Garraway.
Science, 2015 Sep 12; 350(6257). PMID: 26359337    Free PMC article.
Highly Cited.
Acquired resistance to immunotherapy and future challenges.
Nicholas P Restifo, Mark J Smyth, Alexandra Snyder.
Nat Rev Cancer, 2016 Jan 30; 16(2). PMID: 26822578    Free PMC article.
Highly Cited.
CDK4/6 inhibition triggers anti-tumour immunity.
Shom Goel, Molly J DeCristo, +17 authors, Jean J Zhao.
Nature, 2017 Aug 17; 548(7668). PMID: 28813415    Free PMC article.
Highly Cited.
Chromatin states define tumour-specific T cell dysfunction and reprogramming.
Mary Philip, Lauren Fairchild, +11 authors, Andrea Schietinger.
Nature, 2017 May 18; 545(7655). PMID: 28514453    Free PMC article.
Highly Cited.
Trial Watch: Immunomodulatory monoclonal antibodies for oncological indications.
Aitziber Buqué, Norma Bloy, +12 authors, Lorenzo Galluzzi.
Oncoimmunology, 2015 Jul 03; 4(4). PMID: 26137403    Free PMC article.
Checkpoint blockade cancer immunotherapy targets tumour-specific mutant antigens.
Matthew M Gubin, Xiuli Zhang, +24 authors, Robert D Schreiber.
Nature, 2014 Nov 28; 515(7528). PMID: 25428507    Free PMC article.
Highly Cited.
Immune inhibitory molecules LAG-3 and PD-1 synergistically regulate T-cell function to promote tumoral immune escape.
Seng-Ryong Woo, Meghan E Turnis, +18 authors, Dario A A Vignali.
Cancer Res, 2011 Dec 22; 72(4). PMID: 22186141    Free PMC article.
Highly Cited.
Adaptive resistance to therapeutic PD-1 blockade is associated with upregulation of alternative immune checkpoints.
Shohei Koyama, Esra A Akbay, +23 authors, Peter S Hammerman.
Nat Commun, 2016 Feb 18; 7. PMID: 26883990    Free PMC article.
Highly Cited.
Neoantigens in cancer immunotherapy.
Ton N Schumacher, Robert D Schreiber.
Science, 2015 Apr 04; 348(6230). PMID: 25838375
Highly Cited. Review.
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma.
James Larkin, F Stephen Hodi, Jedd D Wolchok.
N Engl J Med, 2015 Sep 24; 373(13). PMID: 26398076
Highly Cited.
Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma.
Willy Hugo, Jesse M Zaretsky, +15 authors, Roger S Lo.
Cell, 2016 Mar 22; 165(1). PMID: 26997480    Free PMC article.
Highly Cited.
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy.
Padmanee Sharma, Siwen Hu-Lieskovan, Jennifer A Wargo, Antoni Ribas.
Cell, 2017 Feb 12; 168(4). PMID: 28187290    Free PMC article.
Highly Cited. Review.
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency.
Dung T Le, Jennifer N Uram, +32 authors, Luis A Diaz.
N Engl J Med, 2015 Jun 02; 372(26). PMID: 26028255    Free PMC article.
Highly Cited.
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma.
Jesse M Zaretsky, Angel Garcia-Diaz, +26 authors, Antoni Ribas.
N Engl J Med, 2016 Jul 20; 375(9). PMID: 27433843    Free PMC article.
Highly Cited.
Boosting antitumor responses of T lymphocytes infiltrating human prostate cancers.
Vincenzo Bronte, Tihana Kasic, +8 authors, Antonella Viola.
J Exp Med, 2005 Apr 13; 201(8). PMID: 15824085    Free PMC article.
Highly Cited.
Tumor Interferon Signaling Regulates a Multigenic Resistance Program to Immune Checkpoint Blockade.
Joseph L Benci, Bihui Xu, +16 authors, Andy J Minn.
Cell, 2016 Dec 03; 167(6). PMID: 27912061    Free PMC article.
Highly Cited.
Resistance to PD1/PDL1 checkpoint inhibition.
Jake S O'Donnell, Georgina V Long, +2 authors, Mark J Smyth.
Cancer Treat Rev, 2016 Dec 13; 52. PMID: 27951441
Highly Cited. Review.
Defining CD8+ T cells that provide the proliferative burst after PD-1 therapy.
Se Jin Im, Masao Hashimoto, +13 authors, Rafi Ahmed.
Nature, 2016 Aug 09; 537(7620). PMID: 27501248    Free PMC article.
Highly Cited.
Fc-dependent depletion of tumor-infiltrating regulatory T cells co-defines the efficacy of anti-CTLA-4 therapy against melanoma.
Tyler R Simpson, Fubin Li, +11 authors, Sergio A Quezada.
J Exp Med, 2013 Jul 31; 210(9). PMID: 23897981    Free PMC article.
Highly Cited.
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors.
Jonathan M Pitt, Marie Vétizou, +8 authors, Laurence Zitvogel.
Immunity, 2016 Jun 23; 44(6). PMID: 27332730
Highly Cited. Review.
Selective expansion of a subset of exhausted CD8 T cells by alphaPD-L1 blockade.
Shawn D Blackburn, Haina Shin, Gordon J Freeman, E John Wherry.
Proc Natl Acad Sci U S A, 2008 Sep 24; 105(39). PMID: 18809920    Free PMC article.
Highly Cited.
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations.
Daniel Sanghoon Shin, Jesse M Zaretsky, +24 authors, Antoni Ribas.
Cancer Discov, 2016 Dec 03; 7(2). PMID: 27903500    Free PMC article.
Highly Cited.
Next generation of immune checkpoint therapy in cancer: new developments and challenges.
Julian A Marin-Acevedo, Bhagirathbhai Dholaria, +3 authors, Yanyan Lou.
J Hematol Oncol, 2018 Mar 17; 11(1). PMID: 29544515    Free PMC article.
Highly Cited. Review.
Beyond the Edge of Hypomethylating Agents: Novel Combination Strategies for Older Adults with Advanced MDS and AML.
Anne Sophie Kubasch, Uwe Platzbecker.
Cancers (Basel), 2018 May 26; 10(6). PMID: 29795051    Free PMC article.
PD-1/PD-L1 immune checkpoint inhibitors in advanced cervical cancer.
Ozlen Saglam, Jose Conejo-Garcia.
Integr Cancer Sci Ther, 2018 Jun 30; 5(2). PMID: 29955379    Free PMC article.
Efficacy of metformin in combination with immune checkpoint inhibitors (anti-PD-1/anti-CTLA-4) in metastatic malignant melanoma.
Muhammad Zubair Afzal, Rima R Mercado, Keisuke Shirai.
J Immunother Cancer, 2018 Jul 04; 6(1). PMID: 29966520    Free PMC article.
Immune cell profiling in the age of immune checkpoint inhibitors: implications for biomarker discovery and understanding of resistance mechanisms.
Su Yin Lim, Helen Rizos.
Mamm Genome, 2018 Jul 04; 29(11-12). PMID: 29968076    Free PMC article.
B7H3 As a Promoter of Metastasis and Promising Therapeutic Target.
Peixin Dong, Ying Xiong, +2 authors, Hidemichi Watari.
Front Oncol, 2018 Jul 24; 8. PMID: 30035102    Free PMC article.
Resistance to Radiotherapy and PD-L1 Blockade Is Mediated by TIM-3 Upregulation and Regulatory T-Cell Infiltration.
Ayman Oweida, Mohammad K Hararah, +14 authors, Sana D Karam.
Clin Cancer Res, 2018 Jul 26; 24(21). PMID: 30042205    Free PMC article.
Highly Cited.
Immune cell subset differentiation and tissue inflammation.
Pu Fang, Xinyuan Li, +7 authors, Hong Wang.
J Hematol Oncol, 2018 Aug 02; 11(1). PMID: 30064449    Free PMC article.
Difference Between Left-Sided and Right-Sided Colorectal Cancer: A Focused Review of Literature.
Burcin Baran, Nazli Mert Ozupek, +3 authors, Yasemin Baskin.
Gastroenterology Res, 2018 Aug 18; 11(4). PMID: 30116425    Free PMC article.
Highly Cited. Review.
Presence of few PD-1-expressing tumor-infiltrating immune cells is a potential predictor of improved response to salvage chemotherapy following nivolumab for non-small cell lung cancer: An exploratory case series.
Daiki Ogawara, Hiroshi Soda, +12 authors, Hiroshi Mukae.
Thorac Cancer, 2018 Aug 21; 9(10). PMID: 30126069    Free PMC article.
Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors.
Ming Yi, Dechao Jiao, +4 authors, Kongming Wu.
Mol Cancer, 2018 Aug 25; 17(1). PMID: 30139382    Free PMC article.
Highly Cited. Review.
3D microfluidic ex vivo culture of organotypic tumor spheroids to model immune checkpoint blockade.
Amir R Aref, Marco Campisi, +20 authors, Russell W Jenkins.
Lab Chip, 2018 Sep 06; 18(20). PMID: 30183789    Free PMC article.
The Combined Use of Melatonin and an Indoleamine 2,3-Dioxygenase-1 Inhibitor Enhances Vaccine-Induced Protective Cellular Immunity to HPV16-Associated Tumors.
Ana C R Moreno, Bruna F M M Porchia, +8 authors, Luís C de Souza Ferreira.
Front Immunol, 2018 Sep 07; 9. PMID: 30186285    Free PMC article.
Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma.
Ronan Flippot, Bernard Escudier, Laurence Albiges.
Drugs, 2018 Sep 07; 78(14). PMID: 30187355
Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy.
Guozhu Xie, Tan Cheng, +6 authors, Yawei Yuan.
J Immunother Cancer, 2018 Sep 14; 6(1). PMID: 30208943    Free PMC article.
Co-inhibition of TIGIT, PD1, and Tim3 reverses dysfunction of Wilms tumor protein-1 (WT1)-specific CD8+ T lymphocytes after dendritic cell vaccination in gastric cancer.
Xu Lu, Jingwei Liu, +8 authors, Lin Yang.
Am J Cancer Res, 2018 Sep 14; 8(8). PMID: 30210924    Free PMC article.
Combination anti-PD-1 and antiretroviral therapy provides therapeutic benefit against SIV.
Geetha H Mylvaganam, Lynette S Chea, +9 authors, Rama R Amara.
JCI Insight, 2018 Sep 21; 3(18). PMID: 30232277    Free PMC article.
Highly Cited.
Not All Immune Checkpoints Are Created Equal.
Annika De Sousa Linhares, Judith Leitner, Katharina Grabmeier-Pfistershammer, Peter Steinberger.
Front Immunol, 2018 Sep 21; 9. PMID: 30233564    Free PMC article.
Highly Cited. Review.
Turn Back the TIMe: Targeting Tumor Infiltrating Myeloid Cells to Revert Cancer Progression.
Robin Maximilian Awad, Yannick De Vlaeminck, +2 authors, Karine Breckpot.
Front Immunol, 2018 Sep 21; 9. PMID: 30233579    Free PMC article.
Highly Cited. Review.
Comprehensive analysis of the tumor immune micro-environment in non-small cell lung cancer for efficacy of checkpoint inhibitor.
Jeong-Sun Seo, Ahreum Kim, Jong-Yeon Shin, Young Tae Kim.
Sci Rep, 2018 Oct 03; 8(1). PMID: 30275546    Free PMC article.
Combination systemic therapies with immune checkpoint inhibitors in pancreatic cancer: overcoming resistance to single-agent checkpoint blockade.
Jun Gong, Andrew Hendifar, +5 authors, Ravi Salgia.
Clin Transl Med, 2018 Oct 09; 7(1). PMID: 30294755    Free PMC article.
Integrin αvβ8-expressing tumor cells evade host immunity by regulating TGF-β activation in immune cells.
Naoki Takasaka, Robert I Seed, +17 authors, Stephen L Nishimura.
JCI Insight, 2018 Oct 20; 3(20). PMID: 30333313    Free PMC article.
[Mode of action, new targets and potential biomarkers in modern immunotherapy].
J Bedke, V Stühler, T Todenhöfer, A Stenzl.
Urologe A, 2018 Oct 24; 57(11). PMID: 30350128
Oncolytic viruses and checkpoint inhibitors: combination therapy in clinical trials.
Christopher J LaRocca, Susanne G Warner.
Clin Transl Med, 2018 Nov 15; 7(1). PMID: 30426287    Free PMC article.
Highly Cited. Review.
Sepsis and Nosocomial Infection: Patient Characteristics, Mechanisms, and Modulation.
Scott J Denstaedt, Benjamin H Singer, Theodore J Standiford.
Front Immunol, 2018 Nov 22; 9. PMID: 30459764    Free PMC article.
Renin-angiotensin inhibitors reprogram tumor immune microenvironment: A comprehensive view of the influences on anti-tumor immunity.
Dora L Vallejo-Ardila, Theodora Fifis, +2 authors, Christopher Christophi.
Oncotarget, 2018 Nov 23; 9(84). PMID: 30464806    Free PMC article.
Implementing tumor mutational burden (TMB) analysis in routine diagnostics-a primer for molecular pathologists and clinicians.
Michael Allgäuer, Jan Budczies, +13 authors, Albrecht Stenzinger.
Transl Lung Cancer Res, 2018 Dec 07; 7(6). PMID: 30505715    Free PMC article.
Highly Cited. Review.
Integrated analysis of the immunological and genetic status in and across cancer types: impact of mutational signatures beyond tumor mutational burden.
Jan Budczies, Anja Seidel, +7 authors, Carsten Denkert.
Oncoimmunology, 2018 Dec 14; 7(12). PMID: 30524909    Free PMC article.
Immunometabolism: A new target for improving cancer immunotherapy.
Chunqing Guo, Shixian Chen, +5 authors, Xiang-Yang Wang.
Adv Cancer Res, 2019 Jun 17; 143. PMID: 31202359    Free PMC article.
Application of PD-1 Blockade in Cancer Immunotherapy.
Xiaomo Wu, Zhongkai Gu, +4 authors, Xiaolong Liu.
Comput Struct Biotechnol J, 2019 Jun 18; 17. PMID: 31205619    Free PMC article.
Highly Cited. Review.
Rebalancing Protein Homeostasis Enhances Tumor Antigen Presentation.
Alex M Jaeger, Lauren Stopfer, +9 authors, Luke Whitesell.
Clin Cancer Res, 2019 Jun 20; 25(21). PMID: 31213460    Free PMC article.
Cancer the'RBP'eutics-RNA-binding proteins as therapeutic targets for cancer.
Shakur Mohibi, Xinbin Chen, Jin Zhang.
Pharmacol Ther, 2019 Jul 16; 203. PMID: 31302171    Free PMC article.
Novel Delivery Systems for Checkpoint Inhibitors.
Purushottam Lamichhane, Rahul Deshmukh, +8 authors, Narottam Lamichhane.
Medicines (Basel), 2019 Aug 03; 6(3). PMID: 31373327    Free PMC article.
PTEN Alterations as a Potential Mechanism for Tumor Cell Escape from PD-1/PD-L1 Inhibition.
Daniele Cretella, Graziana Digiacomo, Elisa Giovannetti, Andrea Cavazzoni.
Cancers (Basel), 2019 Sep 11; 11(9). PMID: 31500143    Free PMC article.
CD8+ and Regulatory T cells Differentiate Tumor Immune Phenotypes and Predict Survival in Locally Advanced Head and Neck Cancer.
Alessia Echarti, Markus Hecht, +4 authors, Luitpold Distel.
Cancers (Basel), 2019 Sep 25; 11(9). PMID: 31546872    Free PMC article.
Monoclonal Antibodies in Dermatooncology-State of the Art and Future Perspectives.
Malgorzata Bobrowicz, Radoslaw Zagozdzon, +3 authors, Magdalena Winiarska.
Cancers (Basel), 2019 Sep 27; 11(10). PMID: 31554169    Free PMC article.
Melanoma plasticity and phenotypic diversity: therapeutic barriers and opportunities.
Florian Rambow, Jean-Christophe Marine, Colin R Goding.
Genes Dev, 2019 Oct 03; 33(19-20). PMID: 31575676    Free PMC article.
Classical Hodgkin's Lymphoma in the Era of Immune Checkpoint Inhibition.
Valli De Re, Laura Caggiari, +2 authors, Maurizio Mascarin.
J Clin Med, 2019 Oct 05; 8(10). PMID: 31581738    Free PMC article.
Impact of the microbiome on checkpoint inhibitor treatment in patients with non-small cell lung cancer and melanoma.
Fyza Y Shaikh, Joell J Gills, Cynthia L Sears.
EBioMedicine, 2019 Oct 11; 48. PMID: 31597596    Free PMC article.
Liver graft rejection following immune checkpoint inhibitors treatment: a review.
Bo Hu, Xiao-Bo Yang, Xin-Ting Sang.
Med Oncol, 2019 Oct 13; 36(11). PMID: 31605245
Clinical outcomes in non-small-cell lung cancer patients receiving concurrent metformin and immune checkpoint inhibitors.
Muhammad Z Afzal, Konstantin Dragnev, Tayyaba Sarwar, Keisuke Shirai.
Lung Cancer Manag, 2019 Oct 28; 8(2). PMID: 31645894    Free PMC article.
Redefining malignant pleural mesothelioma types as a continuum uncovers immune-vascular interactions.
Nicolas Alcala, Lise Mangiante, +39 authors, Lynnette Fernandez-Cuesta.
EBioMedicine, 2019 Oct 28; 48. PMID: 31648983    Free PMC article.
Heterogenous responses to nivolumab in a single metastatic nodule in hepatocellular carcinoma: role of salvage surgery.
Hyun Yang, Pil Soo Sung, +4 authors, Si Hyun Bae.
Hepatobiliary Surg Nutr, 2019 Nov 02; 8(5). PMID: 31673562    Free PMC article.
Targeting the Immune Microenvironment in the Treatment of Head and Neck Squamous Cell Carcinoma.
Hui-Ching Wang, Leong-Perng Chan, Shih-Feng Cho.
Front Oncol, 2019 Nov 05; 9. PMID: 31681613    Free PMC article.
Delivery strategies of cancer immunotherapy: recent advances and future perspectives.
Zhongwei Zhao, Liyun Zheng, +3 authors, Jiansong Ji.
J Hematol Oncol, 2019 Nov 30; 12(1). PMID: 31779642    Free PMC article.
Immunotherapy - Strategies for Expanding Its Role in the Treatment of All Major Tumor Sites.
Chandan Sanghera, Rohan Sanghera.
Cureus, 2019 Dec 04; 11(10). PMID: 31788395    Free PMC article.
Molecular and immune correlates of TIM-3 (HAVCR2) and galectin 9 (LGALS9) mRNA expression and DNA methylation in melanoma.
Tobias A W Holderried, Luka de Vos, +8 authors, Dimo Dietrich.
Clin Epigenetics, 2019 Nov 22; 11(1). PMID: 31747929    Free PMC article.
Development and clinical applications of cancer immunotherapy against PD-1 signaling pathway.
Grace Wakabayashi, Yu-Ching Lee, +3 authors, Yun Yen.
J Biomed Sci, 2019 Dec 06; 26(1). PMID: 31801525    Free PMC article.
Stereotactic Body Radiation and Interleukin-12 Combination Therapy Eradicates Pancreatic Tumors by Repolarizing the Immune Microenvironment.
Bradley N Mills, Kelli A Connolly, +16 authors, Scott A Gerber.
Cell Rep, 2019 Oct 10; 29(2). PMID: 31597100    Free PMC article.
The CC' loop of IgV domains of the immune checkpoint receptors, plays a key role in receptor:ligand affinity modulation.
Shankar V Kundapura, Udupi A Ramagopal.
Sci Rep, 2019 Dec 18; 9(1). PMID: 31844079    Free PMC article.
Recruitment of CD103+ dendritic cells via tumor-targeted chemokine delivery enhances efficacy of checkpoint inhibitor immunotherapy.
John-Michael Williford, Jun Ishihara, +6 authors, Jeffrey A Hubbell.
Sci Adv, 2019 Dec 18; 5(12). PMID: 31844672    Free PMC article.
Overcoming malignant cell-based mechanisms of resistance to immune checkpoint blockade antibodies.
Reham Ajina, David J Zahavi, Yong-Wei Zhang, Louis M Weiner.
Semin Cancer Biol, 2019 Dec 24; 65. PMID: 31866479    Free PMC article.
Cumulative Antibiotic Use Significantly Decreases Efficacy of Checkpoint Inhibitors in Patients with Advanced Cancer.
Nadina Tinsley, Cong Zhou, +8 authors, Natalie Cook.
Oncologist, 2019 Jul 12; 25(1). PMID: 31292268    Free PMC article.
Current Status of Immunotherapy for Lung Cancer and Future Perspectives.
Ho Cheol Kim, Chang Min Choi.
Tuberc Respir Dis (Seoul), 2020 Jan 07; 83(1). PMID: 31905428    Free PMC article.
Enapotamab vedotin, an AXL-specific antibody-drug conjugate, shows preclinical antitumor activity in non-small cell lung cancer.
Louise A Koopman, Mikkel G Terp, +12 authors, Henrik J Ditzel.
JCI Insight, 2019 Oct 11; 4(21). PMID: 31600169    Free PMC article.
Rapid Affinity Maturation of Novel Anti-PD-L1 Antibodies by a Fast Drop of the Antigen Concentration and FACS Selection of Yeast Libraries.
Biancamaria Cembrola, Valentino Ruzza, +13 authors, Alfredo Nicosia.
Biomed Res Int, 2020 Jan 25; 2019. PMID: 31976323    Free PMC article.
Therapeutic Monoclonal Antibodies Targeting Immune Checkpoints for the Treatment of Solid Tumors.
Nicholas Gravbrot, Kacy Gilbert-Gard, +4 authors, Srinath Sundararajan.
Antibodies (Basel), 2019 Oct 24; 8(4). PMID: 31640266    Free PMC article.
Immune gene signatures for predicting durable clinical benefit of anti-PD-1 immunotherapy in patients with non-small cell lung cancer.
Sohyun Hwang, Ah-Young Kwon, +7 authors, Hee Jung An.
Sci Rep, 2020 Jan 22; 10(1). PMID: 31959763    Free PMC article.
FOXD3 Regulates VISTA Expression in Melanoma.
Sheera R Rosenbaum, Meghan Knecht, +11 authors, Andrew E Aplin.
Cell Rep, 2020 Jan 16; 30(2). PMID: 31940493    Free PMC article.
Targeted literature review on use of tumor mutational burden status and programmed cell death ligand 1 expression to predict outcomes of checkpoint inhibitor treatment.
Tina Krieger, Isobel Pearson, +2 authors, Paul Robbins.
Diagn Pathol, 2020 Feb 01; 15(1). PMID: 32000815    Free PMC article.
An intrinsic role of IL-33 in Treg cell-mediated tumor immunoevasion.
Aikaterini Hatzioannou, Aggelos Banos, +15 authors, Panayotis Verginis.
Nat Immunol, 2019 Dec 18; 21(1). PMID: 31844326    Free PMC article.
Mouse PVRIG Has CD8+ T Cell-Specific Coinhibitory Functions and Dampens Antitumor Immunity.
Benjamin Murter, Xiaoyu Pan, +16 authors, Sudipto Ganguly.
Cancer Immunol Res, 2019 Jan 20; 7(2). PMID: 30659055    Free PMC article.
My journey from tyrosine phosphorylation inhibitors to targeted immune therapy as strategies to combat cancer.
Alexander Levitzki, Shoshana Klein.
Proc Natl Acad Sci U S A, 2019 May 12; 116(24). PMID: 31076554    Free PMC article.
Differential expression of individual transcript variants of PD-1 and PD-L2 genes on Th-1/Th-2 status is guaranteed for prognosis prediction in PCNSL.
Yasuo Takashima, Atsushi Kawaguchi, +12 authors, Ryuya Yamanaka.
Sci Rep, 2019 Jul 12; 9(1). PMID: 31292525    Free PMC article.
A Bis-Indole-Derived NR4A1 Antagonist Induces PD-L1 Degradation and Enhances Antitumor Immunity.
Keshav Karki, Gus A Wright, +3 authors, Stephen Safe.
Cancer Res, 2020 Jan 09; 80(5). PMID: 31911554    Free PMC article.
Functional genomics: paving the way for more successful cancer immunotherapy.
Reham Ajina, Danielle Zamalin, Louis M Weiner.
Brief Funct Genomics, 2018 May 16; 18(2). PMID: 29762641    Free PMC article.
Acquired resistance to cancer immunotherapy.
Arianna Draghi, Christopher Aled Chamberlain, Andrew Furness, Marco Donia.
Semin Immunopathol, 2018 Jul 04; 41(1). PMID: 29968044
Rapid disease progression in a patient with mismatch repair-deficient and cortisol secreting adrenocortical carcinoma treated with pembrolizumab.
R T Casey, O Giger, +12 authors, B G Challis.
Semin Oncol, 2018 Sep 29; 45(3). PMID: 30262398    Free PMC article.
Linking Autophagy and the Dysregulated NFκB/ SNAIL/YY1/RKIP/PTEN Loop in Cancer: Therapeutic Implications.
Benjamin Bonavida.
Crit Rev Oncog, 2018 Oct 13; 23(5-6). PMID: 30311562    Free PMC article.
Immune biomarkers of response to immune-checkpoint inhibitors in head and neck squamous cell carcinoma.
M Oliva, A Spreafico, +4 authors, L L Siu.
Ann Oncol, 2018 Nov 22; 30(1). PMID: 30462163    Free PMC article.
Immune checkpoint inhibitors: recent progress and potential biomarkers.
Pramod Darvin, Salman M Toor, Varun Sasidharan Nair, Eyad Elkord.
Exp Mol Med, 2018 Dec 14; 50(12). PMID: 30546008    Free PMC article.
Highly Cited. Review.
Design of Peptide-Based Nanovaccines Targeting Leading Antigens From Gynecological Cancers to Induce HLA-A2.1 Restricted CD8+ T Cell Responses.
Sue D Xiang, Kirsty L Wilson, +2 authors, Magdalena Plebanski.
Front Immunol, 2019 Jan 12; 9. PMID: 30631324    Free PMC article.
Emerging Cellular Therapies: T Cells and Beyond.
Stephen Todryk, Agnieszka Jozwik, Julian de Havilland, Joanna Hester.
Cells, 2019 Mar 29; 8(3). PMID: 30917514    Free PMC article.
A network approach to developing immuno-oncology combinations in Canada.
V Higenell, R Fajzel, +11 authors, S Verma.
Curr Oncol, 2019 May 03; 26(2). PMID: 31043804    Free PMC article.
Inhibition of host NOX1 blocks tumor growth and enhances checkpoint inhibitor-based immunotherapy.
Jimmy Stalin, Sarah Garrido-Urbani, +5 authors, Beat A Imhof.
Life Sci Alliance, 2019 Jun 30; 2(4). PMID: 31249132    Free PMC article.
Enhancing the Efficacy of Melanocortin 1 Receptor-Targeted Radiotherapy by Pharmacologically Upregulating the Receptor in Metastatic Melanoma.
Mengshi Li, Dijie Liu, +9 authors, Michael K Schultz.
Mol Pharm, 2019 Jul 19; 16(9). PMID: 31318566    Free PMC article.
NQO1 targeting prodrug triggers innate sensing to overcome checkpoint blockade resistance.
Xiaoguang Li, Zhida Liu, +8 authors, Yang-Xin Fu.
Nat Commun, 2019 Jul 22; 10(1). PMID: 31324798    Free PMC article.
Syringeable immunotherapeutic nanogel reshapes tumor microenvironment and prevents tumor metastasis and recurrence.
Chanyoung Song, Hathaichanok Phuengkham, +13 authors, Yong Taik Lim.
Nat Commun, 2019 Aug 23; 10(1). PMID: 31431623    Free PMC article.
Oncolytic poxvirus CF33-hNIS-ΔF14.5 favorably modulates tumor immune microenvironment and works synergistically with anti-PD-L1 antibody in a triple-negative breast cancer model.
Shyambabu Chaurasiya, Annie Yang, +8 authors, Yuman Fong.
Oncoimmunology, 2020 Mar 12; 9(1). PMID: 32158622    Free PMC article.
Tumor Drug Penetration Measurements Could Be the Neglected Piece of the Personalized Cancer Treatment Puzzle.
Imke H Bartelink, Ella F Jones, +12 authors, Geraldine Gebhart.
Clin Pharmacol Ther, 2018 Aug 15; 106(1). PMID: 30107040    Free PMC article.
A Natural Impact: NK Cells at the Intersection of Cancer and HIV Disease.
Olivier Lucar, R Keith Reeves, Stephanie Jost.
Front Immunol, 2019 Sep 03; 10. PMID: 31474977    Free PMC article.
Current Advances in the Treatment of BRAF-Mutant Melanoma.
Hima Patel, Nour Yacoub, +4 authors, Joan T Garrett.
Cancers (Basel), 2020 Feb 26; 12(2). PMID: 32092958    Free PMC article.
Radiofrequency ablation of liver metastasis: potential impact on immune checkpoint inhibitor therapy.
Yasunori Minami, Naoshi Nishida, Masatoshi Kudo.
Eur Radiol, 2019 Apr 10; 29(9). PMID: 30963271
Addressing Recent Failures in Immuno-Oncology Trials to Guide Novel Immunotherapeutic Treatment Strategies.
Shazia K Nakhoda, Anthony J Olszanski.
Pharmaceut Med, 2020 Mar 12; 34(2). PMID: 32157638    Free PMC article.
Tumor cell-intrinsic PD-1 receptor is a tumor suppressor and mediates resistance to PD-1 blockade therapy.
Xiaodong Wang, Xiaohui Yang, +21 authors, Shan Gao.
Proc Natl Acad Sci U S A, 2020 Mar 13; 117(12). PMID: 32161124    Free PMC article.
Single-Cell Approaches to Profile the Response to Immune Checkpoint Inhibitors.
Lara Gibellini, Sara De Biasi, +5 authors, Andrea Cossarizza.
Front Immunol, 2020 Apr 09; 11. PMID: 32265933    Free PMC article.
Naturally Killing the Silent Killer: NK Cell-Based Immunotherapy for Ovarian Cancer.
Sarah Nersesian, Haley Glazebrook, +2 authors, Jeanette E Boudreau.
Front Immunol, 2019 Aug 29; 10. PMID: 31456796    Free PMC article.
Overexpression of PDE4A Acts as Checkpoint Inhibitor Against cAMP-Mediated Immunosuppression in vitro.
Klaus G Schmetterer, Katrin Goldhahn, +10 authors, Rodrig Marculescu.
Front Immunol, 2019 Aug 17; 10. PMID: 31417563    Free PMC article.
TNF-α inhibitor reduces drug-resistance to anti-PD-1: A mathematical model.
Xiulan Lai, Wenrui Hao, Avner Friedman.
PLoS One, 2020 Apr 21; 15(4). PMID: 32310956    Free PMC article.
Transcriptional downregulation of MHC class I and melanoma de- differentiation in resistance to PD-1 inhibition.
Jenny H Lee, Elena Shklovskaya, +15 authors, Helen Rizos.
Nat Commun, 2020 Apr 22; 11(1). PMID: 32312968    Free PMC article.
Pharmaceutical patents: reconciling the human right to health with the incentive to invent.
Levon M Khachigian.
Drug Discov Today, 2020 Apr 24; 25(7). PMID: 32325020    Free PMC article.
Inhibiting Notch1 enhances immunotherapy efficacy in melanoma by preventing Notch1 dependent immune suppressive properties.
Hong Qiu, Patrick M Zmina, +2 authors, Barbara Bedogni.
Cancer Lett, 2018 Jul 24; 434. PMID: 30036609    Free PMC article.
Bispecific Antibodies in the Treatment of Hematologic Malignancies.
Johannes Duell, Philip E Lammers, +4 authors, Saar Gill.
Clin Pharmacol Ther, 2019 Feb 17; 106(4). PMID: 30770546    Free PMC article.
Identification of the immune checkpoint signature of multiple myeloma using mass cytometry-based single-cell analysis.
Jinheng Wang, Yongjiang Zheng, +4 authors, Jinbao Liu.
Clin Transl Immunology, 2020 May 02; 9(5). PMID: 32355560    Free PMC article.
Heterogeneous responses in hepatocellular carcinoma: the achilles heel of immune checkpoint inhibitors.
Zuyuan Lin, Di Lu, +2 authors, Xiao Xu.
Am J Cancer Res, 2020 May 06; 10(4). PMID: 32368387    Free PMC article.
Transcriptional Upregulation of NLRC5 by Radiation Drives STING- and Interferon-Independent MHC-I Expression on Cancer Cells and T Cell Cytotoxicity.
Lauren K Zebertavage, Alejandro Alice, Marka R Crittenden, Michael J Gough.
Sci Rep, 2020 May 02; 10(1). PMID: 32355214    Free PMC article.
High endothelial venules are associated with microsatellite instability, hereditary background and immune evasion in colorectal cancer.
Pauline L Pfuderer, Alexej Ballhausen, +7 authors, Aysel Ahadova.
Br J Cancer, 2019 Jul 31; 121(5). PMID: 31358939    Free PMC article.
Loss of BAP1 expression is associated with an immunosuppressive microenvironment in uveal melanoma, with implications for immunotherapy development.
Carlos R Figueiredo, Helen Kalirai, +5 authors, Sarah E Coupland.
J Pathol, 2020 Jan 22; 250(4). PMID: 31960425    Free PMC article.
Overcoming resistance to anti-PD1 and anti-PD-L1 treatment in gastrointestinal malignancies.
Alberto Puccini, Francesca Battaglin, +2 authors, Mohamed E Salem.
J Immunother Cancer, 2020 May 13; 8(1). PMID: 32393474    Free PMC article.
Anti-OX40 Antibody Directly Enhances The Function of Tumor-Reactive CD8+ T Cells and Synergizes with PI3Kβ Inhibition in PTEN Loss Melanoma.
Weiyi Peng, Leila J Williams, +17 authors, Patrick Hwu.
Clin Cancer Res, 2019 Aug 03; 25(21). PMID: 31371342    Free PMC article.
VISTA: a novel immunotherapy target for normalizing innate and adaptive immunity.
Mohamed A ElTanbouly, Walburga Croteau, Randolph J Noelle, J Louise Lines.
Semin Immunol, 2019 Oct 13; 42. PMID: 31604531    Free PMC article.
Primary Resistance to PD-1-Based Immunotherapy-A Study in 319 Patients with Stage IV Melanoma.
Teresa Amaral, Olivia Seeber, +8 authors, Claus Garbe.
Cancers (Basel), 2020 Apr 26; 12(4). PMID: 32331243    Free PMC article.
A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma.
Ricarda M Hoffmann, Silvia Crescioli, +9 authors, Sophia N Karagiannis.
Cancers (Basel), 2020 Apr 26; 12(4). PMID: 32331483    Free PMC article.
Current Approaches for Combination Therapy of Cancer: The Role of Immunogenic Cell Death.
Zahra Asadzadeh, Elham Safarzadeh, +7 authors, Behzad Baradaran.
Cancers (Basel), 2020 Apr 29; 12(4). PMID: 32340275    Free PMC article.
Programmed cell death protein-1 (PD1) expression in the microenvironment of classical Hodgkin lymphoma is similar between favorable and adverse outcome and does not enrich over serial relapses with conventional chemotherapy.
Joseph G Taylor, Andrew Clear, Maria Calaminici, John G Gribben.
Haematologica, 2019 Jan 02; 104(1). PMID: 30598496    Free PMC article.
Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment.
Stephanie Sasse, Katharina Reddemann, +6 authors, Wolfram Klapper.
Haematologica, 2019 Jan 02; 104(1). PMID: 30598497    Free PMC article.
Long-Term Outcomes and Responses to Retreatment in Patients With Melanoma Treated With PD-1 Blockade.
Allison Betof Warner, Jessica S Palmer, +9 authors, Paul B Chapman.
J Clin Oncol, 2020 Feb 14; 38(15). PMID: 32053428    Free PMC article.
Molecular targeting of renal cell carcinoma by an oral combination.
Andre R Jordan, Jiaojiao Wang, +11 authors, Vinata B Lokeshwar.
Oncogenesis, 2020 May 20; 9(5). PMID: 32427869    Free PMC article.
Talkin' Toxins: From Coley's to Modern Cancer Immunotherapy.
Robert D Carlson, John C Flickinger, Adam E Snook.
Toxins (Basel), 2020 Apr 15; 12(4). PMID: 32283684    Free PMC article.
Immunotherapy After Immunotherapy: Response Rescue in a Patient With Microsatellite Instability-high Colorectal Cancer Post-Pembrolizumab.
Satya Das, Audrey Allen, Jordan Berlin.
Clin Colorectal Cancer, 2020 Mar 09; 19(2). PMID: 32146081    Free PMC article.
Sevoflurane depletes macrophages from the melanoma microenvironment.
Isabella Sztwiertnia, Judith Schenz, +5 authors, Florian Uhle.
PLoS One, 2020 May 30; 15(5). PMID: 32470095    Free PMC article.
Integration of Digital Pathologic and Transcriptomic Analyses Connects Tumor-Infiltrating Lymphocyte Spatial Density With Clinical Response to BRAF Inhibitors.
Arturas Ziemys, Michelle Kim, +6 authors, Genevieve Boland.
Front Oncol, 2020 Jun 13; 10. PMID: 32528881    Free PMC article.
Beta-Adrenergic Signaling in Tumor Immunology and Immunotherapy.
Wei Wang, Xuefang Cao.
Crit Rev Immunol, 2019 Nov 05; 39(2). PMID: 31679250    Free PMC article.
cGAS-STING, an important pathway in cancer immunotherapy.
Minlin Jiang, Peixin Chen, +8 authors, Caicun Zhou.
J Hematol Oncol, 2020 Jun 24; 13(1). PMID: 32571374    Free PMC article.
Increased both PD-L1 and PD-L2 expressions on monocytes of patients with hepatocellular carcinoma was associated with a poor prognosis.
Hidetaka Yasuoka, Akira Asai, +3 authors, Kazuhide Higuchi.
Sci Rep, 2020 Jun 27; 10(1). PMID: 32587357    Free PMC article.
Immune Checkpoint Inhibitors in Hepatocellular Cancer: Current Understanding on Mechanisms of Resistance and Biomarkers of Response to Treatment.
Amblessed E Onuma, Hongji Zhang, +3 authors, Allan Tsung.
Gene Expr, 2020 Apr 29; 20(1). PMID: 32340652    Free PMC article.
Manipulation of Metabolic Pathways and Its Consequences for Anti-Tumor Immunity: A Clinical Perspective.
Huang-Yu Yang, Chao-Yi Wu, Jonathan D Powell, Kun-Lin Lu.
Int J Mol Sci, 2020 Jun 10; 21(11). PMID: 32512898    Free PMC article.
Role of DNA repair defects in predicting immunotherapy response.
Jing Zhang, David J H Shih, Shiaw-Yih Lin.
Biomark Res, 2020 Jul 03; 8. PMID: 32612833    Free PMC article.
Dual Vascular Endothelial Growth Factor Receptor and Fibroblast Growth Factor Receptor Inhibition Elicits Antitumor Immunity and Enhances Programmed Cell Death-1 Checkpoint Blockade in Hepatocellular Carcinoma.
Haijing Deng, Anna Kan, +12 authors, Ming Zhao.
Liver Cancer, 2020 Jul 11; 9(3). PMID: 32647635    Free PMC article.
Structural insights into human Arginase-1 pH dependence and its inhibition by the small molecule inhibitor CB-1158.
Yvonne Grobben, Joost C M Uitdehaag, +4 authors, Guido J R Zaman.
J Struct Biol X, 2020 Jul 11; 4. PMID: 32647818    Free PMC article.
Glycogen Synthase Kinase 3β in Cancer Biology and Treatment.
Takahiro Domoto, Masahiro Uehara, Dilireba Bolidong, Toshinari Minamoto.
Cells, 2020 Jun 07; 9(6). PMID: 32503133    Free PMC article.
Combined PARP Inhibition and Immune Checkpoint Therapy in Solid Tumors.
Florent Peyraud, Antoine Italiano.
Cancers (Basel), 2020 Jun 13; 12(6). PMID: 32526888    Free PMC article.
Identification of immunological subtypes of hepatocellular carcinoma with expression profiling of immune-modulating genes.
Di Cao, Meng-Ke Chen, +7 authors, Hui-Yun Wang.
Aging (Albany NY), 2020 Jun 17; 12(12). PMID: 32544882    Free PMC article.
Combination of Ipilimumab and Nivolumab in Cancers: From Clinical Practice to Ongoing Clinical Trials.
Omid Kooshkaki, Afshin Derakhshani, +6 authors, Behzad Baradaran.
Int J Mol Sci, 2020 Jun 26; 21(12). PMID: 32580338    Free PMC article.
Resistance to immune checkpoint inhibitors in non-small cell lung cancer: biomarkers and therapeutic strategies.
Robert J Walsh, Ross A Soo.
Ther Adv Med Oncol, 2020 Jul 17; 12. PMID: 32670423    Free PMC article.
Immunization against ROS1 by DNA Electroporation Impairs K-Ras-Driven Lung Adenocarcinomas ​.
Federica Riccardo, Giuseppina Barutello, +11 authors, Elena Quaglino.
Vaccines (Basel), 2020 Apr 10; 8(2). PMID: 32268572    Free PMC article.
Overcoming Tumor Resistance to Oncolyticvaccinia Virus with Anti-PD-1-Based Combination Therapy by Inducing Antitumor Immunity in the Tumor Microenvironment.
So Young Yoo, Narayanasamy Badrinath, +2 authors, Jeong Heo.
Vaccines (Basel), 2020 Jun 25; 8(2). PMID: 32575351    Free PMC article.
Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus.
Marco Mineo, Shawn M Lyons, +20 authors, E Antonio Chiocca.
Mol Cell, 2020 Jun 07; 78(6). PMID: 32504554    Free PMC article.
Multimodal Multiplexed Immunoimaging with Nanostars to Detect Multiple Immunomarkers and Monitor Response to Immunotherapies.
Yu-Chuan Ou, Xiaona Wen, +14 authors, Rizia Bardhan.
ACS Nano, 2019 Dec 19; 14(1). PMID: 31851488    Free PMC article.
Progesterone/Org inhibits lung adenocarcinoma cell growth via membrane progesterone receptor alpha.
Jian Xiao, Xi Chen, +5 authors, Qiong Chen.
Thorac Cancer, 2020 Jun 13; 11(8). PMID: 32529777    Free PMC article.
Overcoming Genetically Based Resistance Mechanisms to PD-1 Blockade.
Davis Y Torrejon, Gabriel Abril-Rodriguez, +18 authors, Antoni Ribas.
Cancer Discov, 2020 May 30; 10(8). PMID: 32467343    Free PMC article.
Immunotherapies and Combination Strategies for Immuno-Oncology.
Cody Barbari, Tyler Fontaine, +4 authors, Rahul R Deshmukh.
Int J Mol Sci, 2020 Jul 19; 21(14). PMID: 32679922    Free PMC article.
The Latest Findings of PD-1/PD-L1 Inhibitor Application in Gynecologic Cancers.
Omid Kooshkaki, Afshin Derakhshani, +9 authors, Behzad Baradaran.
Int J Mol Sci, 2020 Jul 28; 21(14). PMID: 32708748    Free PMC article.
Comprehensive analyses of immunodynamics and immunoreactivity in response to treatment in ALK-positive non-small-cell lung cancer.
Kyoung-Ho Pyo, Sun Min Lim, +13 authors, Byoung Chul Cho.
J Immunother Cancer, 2020 Jul 31; 8(2). PMID: 32727812    Free PMC article.
Combination of Immune Checkpoint Inhibitors with Chemotherapy in Lung Cancer.
Wei Liu, Lei Zhang, +6 authors, Jianhui Cai.
Onco Targets Ther, 2020 Aug 18; 13. PMID: 32801752    Free PMC article.
Why natural killer cells in triple negative breast cancer?
Mustafa Abdel-Latif, Rana Ahmed Youness.
World J Clin Oncol, 2020 Aug 22; 11(7). PMID: 32821652    Free PMC article.
LAG-3 and PD-1+LAG-3 inhibition promote anti-tumor immune responses in human autologous melanoma/T cell co-cultures.
Nicolas Gestermann, Damien Saugy, +6 authors, Grégory Verdeil.
Oncoimmunology, 2020 Aug 28; 9(1). PMID: 32850194    Free PMC article.
Bacteria-triggered tumor-specific thrombosis to enable potent photothermal immunotherapy of cancer.
Xuan Yi, Hailin Zhou, +5 authors, Zhuang Liu.
Sci Adv, 2020 Aug 28; 6(33). PMID: 32851163    Free PMC article.
Unexpected favorable outcome to sintilimab plus bevacizumab in an EGFR-mutated non-small cell lung cancer patient: A case report.
Yiruo Zhang, Mei Zhao, +2 authors, Yingying Du.
Thorac Cancer, 2020 Jul 14; 11(9). PMID: 32656988    Free PMC article.
Myeloid Cells Orchestrate Systemic Immunosuppression, Impairing the Efficacy of Immunotherapy against HPV+ Cancers.
Gabriele Galliverti, Stephan Wullschleger, +7 authors, Douglas Hanahan.
Cancer Immunol Res, 2019 Nov 28; 8(1). PMID: 31771984    Free PMC article.
Complete and long-lasting clinical responses in immune checkpoint inhibitor-resistant, metastasized melanoma treated with adoptive T cell transfer combined with DC vaccination.
Tanja Lövgren, Maria Wolodarski, +17 authors, Rolf Kiessling.
Oncoimmunology, 2020 Sep 15; 9(1). PMID: 32923156    Free PMC article.
PRMT5 control of cGAS/STING and NLRC5 pathways defines melanoma response to antitumor immunity.
Hyungsoo Kim, Heejung Kim, +4 authors, Ze'ev A Ronai.
Sci Transl Med, 2020 Jul 10; 12(551). PMID: 32641491    Free PMC article.
Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?
Purushottam Lamichhane, Neha P Amin, Manuj Agarwal, Narottam Lamichhane.
Medicines (Basel), 2018 Oct 27; 5(4). PMID: 30360504    Free PMC article.
Analysis of Vipadenant and Its In Vitro and In Vivo Metabolites via Liquid Chromatography-Quadrupole-Time-of-Flight Mass Spectrometry.
Seok-Ho Shin, Min-Ho Park, +5 authors, Young G Shin.
Pharmaceutics, 2018 Dec 06; 10(4). PMID: 30513962    Free PMC article.
Metastatic prostate cancer remains incurable, why?
Liang Dong, Richard C Zieren, +2 authors, Kenneth J Pienta.
Asian J Urol, 2019 Feb 19; 6(1). PMID: 30775246    Free PMC article.
Combinatorial Approach to Improve Cancer Immunotherapy: Rational Drug Design Strategy to Simultaneously Hit Multiple Targets to Kill Tumor Cells and to Activate the Immune System.
Shweta Joshi, Donald L Durden.
J Oncol, 2019 Mar 12; 2019. PMID: 30853982    Free PMC article.
The Position of Inhaled Chemotherapy in the Care of Patients with Lung Tumors: Clinical Feasibility and Indications According to Recent Pharmaceutical Progresses.
Rémi Rosière, Thierry Berghmans, +2 authors, Nathalie Wauthoz.
Cancers (Basel), 2019 Mar 15; 11(3). PMID: 30866545    Free PMC article.
Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients.
Emeric Limagne, Corentin Richard, +6 authors, François Ghiringhelli.
Oncoimmunology, 2019 Mar 25; 8(4). PMID: 30906658    Free PMC article.
Highly Cited.
Maytansine-bearing antibody-drug conjugates induce in vitro hallmarks of immunogenic cell death selectively in antigen-positive target cells.
Maxine Bauzon, Penelope M Drake, +3 authors, David Rabuka.
Oncoimmunology, 2019 Mar 25; 8(4). PMID: 30906660    Free PMC article.
The Discovery of Biomarkers in Cancer Immunotherapy.
Anil P George, Timothy M Kuzel, Yi Zhang, Bin Zhang.
Comput Struct Biotechnol J, 2019 Apr 24; 17. PMID: 31011407    Free PMC article.
An extended overall survival analysis of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced non-squamous non-small cell lung cancer.
Muhammad Zubair Afzal, Konstantin H Dragnev, Keisuke Shirai.
Ann Transl Med, 2019 Apr 30; 7(Suppl 1). PMID: 31032332    Free PMC article.
Liquid biopsy for lung cancer immunotherapy.
Liang-Liang Cai, Jie Wang.
Oncol Lett, 2019 Jun 13; 17(6). PMID: 31186680    Free PMC article.
Liquid Biopsy for the Detection of Resistance Mechanisms in NSCLC: Comparison of Different Blood Biomarkers.
Luigi Pasini, Paola Ulivi.
J Clin Med, 2019 Jul 22; 8(7). PMID: 31323990    Free PMC article.
AP-1 Transcription Factors as Regulators of Immune Responses in Cancer.
Vasileios Atsaves, Vasiliki Leventaki, George Z Rassidakis, Francois X Claret.
Cancers (Basel), 2019 Jul 26; 11(7). PMID: 31340499    Free PMC article.
Phase I Study of the Bifunctional Fusion Protein Bintrafusp Alfa in Asian Patients with Advanced Solid Tumors, Including a Hepatocellular Carcinoma Safety-Assessment Cohort.
Toshihiko Doi, Yutaka Fujiwara, +5 authors, Masatoshi Kudo.
Oncologist, 2020 Apr 24; 25(9). PMID: 32324927    Free PMC article.
Chemically Programmed Vaccines: Iron Catalysis in Nanoparticles Enhances Combination Immunotherapy and Immunotherapy-Promoted Tumor Ferroptosis.
Ane Ruiz-de-Angulo, Marc Bilbao-Asensio, +7 authors, Juan C Mareque-Rivas.
iScience, 2020 Sep 13; 23(9). PMID: 32919370    Free PMC article.
Xenogenization of tumor cells by fusogenic exosomes in tumor microenvironment ignites and propagates antitumor immunity.
Gi Beom Kim, Gi-Hoon Nam, +5 authors, In-San Kim.
Sci Adv, 2020 Sep 17; 6(27). PMID: 32937446    Free PMC article.
Research Status and Outlook of PD-1/PD-L1 Inhibitors for Cancer Therapy.
Leilei Ai, Jian Chen, +4 authors, Xiaochun Yang.
Drug Des Devel Ther, 2020 Sep 29; 14. PMID: 32982171    Free PMC article.
Anti-angiogenic Agents in Combination With Immune Checkpoint Inhibitors: A Promising Strategy for Cancer Treatment.
Yuxiao Song, Yang Fu, +3 authors, Bicheng Zhang.
Front Immunol, 2020 Sep 29; 11. PMID: 32983126    Free PMC article.
An effective peptide vaccine strategy circumventing clonal MHC heterogeneity of murine myeloid leukaemia.
A-Ri Shin, Sang-Eun Lee, +3 authors, Tai-Gyu Kim.
Br J Cancer, 2020 Jul 01; 123(6). PMID: 32595211    Free PMC article.
Development of CDX-527: a bispecific antibody combining PD-1 blockade and CD27 costimulation for cancer immunotherapy.
Laura A Vitale, Li-Zhen He, +15 authors, Tibor Keler.
Cancer Immunol Immunother, 2020 May 27; 69(10). PMID: 32451681    Free PMC article.
Treatment of Advanced Melanoma in 2020 and Beyond.
Russell W Jenkins, David E Fisher.
J Invest Dermatol, 2020 Apr 09; 141(1). PMID: 32268150    Free PMC article.
Conferring receptors on recipient cells with extracellular vesicles for targeted drug delivery.
Zachary Quinn, Wenjun Mao, +2 authors, Yuan Wan.
Bioact Mater, 2020 Oct 08; 6(3). PMID: 33024896    Free PMC article.
Screening Cancer Immunotherapy: When Engineering Approaches Meet Artificial Intelligence.
Xingwu Zhou, Moyuan Qu, +9 authors, Ali Khademhosseini.
Adv Sci (Weinh), 2020 Oct 13; 7(19). PMID: 33042756    Free PMC article.
Treatment of Advanced Melanoma: Past, Present and Future.
Taku Fujimura, Yumi Kambayashi, +2 authors, Setsuya Aiba.
Life (Basel), 2020 Sep 20; 10(9). PMID: 32948031    Free PMC article.
m6 A RNA methyltransferases METTL3/14 regulate immune responses to anti-PD-1 therapy.
Lingling Wang, Hui Hui, +5 authors, Tariq M Rana.
EMBO J, 2020 Sep 24; 39(20). PMID: 32964498    Free PMC article.
Safety and efficacy of AMG 820, an anti-colony-stimulating factor 1 receptor antibody, in combination with pembrolizumab in adults with advanced solid tumors.
Albiruni Ra Razak, James M Cleary, +18 authors, Kyriakos P Papadopoulos.
J Immunother Cancer, 2020 Oct 14; 8(2). PMID: 33046621    Free PMC article.
Deconstructing tumor heterogeneity: the stromal perspective.
Renee E Vickman, Douglas V Faget, +25 authors, Sheila A Stewart.
Oncotarget, 2020 Oct 23; 11(40). PMID: 33088423    Free PMC article.
Nucleic Acid-Based Approaches for Tumor Therapy.
Simone Hager, Frederic Julien Fittler, Ernst Wagner, Matthias Bros.
Cells, 2020 Sep 13; 9(9). PMID: 32917034    Free PMC article.
Targeted Molecular Therapeutics for Bladder Cancer-A New Option beyond the Mixed Fortunes of Immune Checkpoint Inhibitors?
Olga Bednova, Jeffrey V Leyton.
Int J Mol Sci, 2020 Oct 07; 21(19). PMID: 33019653    Free PMC article.
Role of Human Leukocyte Antigen System as A Predictive Biomarker for Checkpoint-Based Immunotherapy in Cancer Patients.
Francesco Sabbatino, Luigi Liguori, +7 authors, Stefano Pepe.
Int J Mol Sci, 2020 Oct 08; 21(19). PMID: 33023239    Free PMC article.
Electroporation as the Immunotherapy Strategy for Cancer in Veterinary Medicine: State of the Art in Latin America.
Felipe Maglietti, Matías Tellado, +4 authors, Guillermo Marshall.
Vaccines (Basel), 2020 Sep 23; 8(3). PMID: 32957424    Free PMC article.
Biomarkers or factors for predicting the efficacy and adverse effects of immune checkpoint inhibitors in lung cancer: achievements and prospective.
Wen-Jia Shi, Wei Zhao.
Chin Med J (Engl), 2020 Sep 23; 133(20). PMID: 32960841    Free PMC article.
Exploration of Feasible Immune Biomarkers for Immune Checkpoint Inhibitors in Head and Neck Squamous Cell Carcinoma Treatment in Real World Clinical Practice.
Hui-Ching Wang, Tsung-Jang Yeh, +2 authors, Shih-Feng Cho.
Int J Mol Sci, 2020 Oct 21; 21(20). PMID: 33076306    Free PMC article.
The Tumor and Host Immune Signature, and the Gut Microbiota as Predictive Biomarkers for Immune Checkpoint Inhibitor Response in Melanoma Patients.
Katarzyna Tomela, Bernadeta Pietrzak, Marcin Schmidt, Andrzej Mackiewicz.
Life (Basel), 2020 Oct 01; 10(10). PMID: 32992737    Free PMC article.
Immunotoxin Screening System: A Rapid and Direct Approach to Obtain Functional Antibodies with Internalization Capacities.
Shusei Hamamichi, Takeshi Fukuhara, Nobutaka Hattori.
Toxins (Basel), 2020 Oct 21; 12(10). PMID: 33076544    Free PMC article.
Challenges and Opportunities in the Clinical Development of STING Agonists for Cancer Immunotherapy.
Leila Motedayen Aval, James E Pease, Rohini Sharma, David J Pinato.
J Clin Med, 2020 Oct 22; 9(10). PMID: 33081170    Free PMC article.
Selective SIRPα blockade reverses tumor T cell exclusion and overcomes cancer immunotherapy resistance.
Vanessa Gauttier, Sabrina Pengam, +40 authors, Nicolas Poirier.
J Clin Invest, 2020 Oct 20; 130(11). PMID: 33074246    Free PMC article.
Human Cancers Express TRAILshort, a Dominant Negative TRAIL Splice Variant, Which Impairs Immune Effector Cell Killing of Tumor Cells.
Fatma Aboulnasr, Ashton Krogman, +16 authors, Andrew D Badley.
Clin Cancer Res, 2020 Jul 17; 26(21). PMID: 32669373    Free PMC article.
The Use of Immune Checkpoint Inhibitors in Oncology and the Occurrence of AKI: Where Do We Stand?
Rossana Franzin, Giuseppe Stefano Netti, +5 authors, Elena Ranieri.
Front Immunol, 2020 Nov 10; 11. PMID: 33162990    Free PMC article.
Mechanisms of hyperprogressive disease after immune checkpoint inhibitor therapy: what we (don't) know.
Simone Camelliti, Valentino Le Noci, +8 authors, Michele Sommariva.
J Exp Clin Cancer Res, 2020 Nov 11; 39(1). PMID: 33168050    Free PMC article.
Emerging Blood-Based Biomarkers for Predicting Response to Checkpoint Immunotherapy in Non-Small-Cell Lung Cancer.
Shumin Li, Chengyan Zhang, Guanchao Pang, Pingli Wang.
Front Immunol, 2020 Nov 13; 11. PMID: 33178229    Free PMC article.
Systematic Review.
Study and analysis of antitumor resistance mechanism of PD1/PD-L1 immune checkpoint blocker.
Zhengyi Wang, Xiaoying Wu.
Cancer Med, 2020 Sep 03; 9(21). PMID: 32875727    Free PMC article.
Concomitant or delayed anti-TNF differentially impact on immune-related adverse events and antitumor efficacy after anti-CD40 therapy.
Celia Jacoberger-Foissac, Stephen J Blake, +5 authors, Michele Wl Teng.
J Immunother Cancer, 2020 Nov 18; 8(2). PMID: 33199513    Free PMC article.
Plasma-derived extracellular vesicle analysis and deconvolution enable prediction and tracking of melanoma checkpoint blockade outcome.
Alvin Shi, Gyulnara G Kasumova, +13 authors, Genevieve M Boland.
Sci Adv, 2020 Nov 15; 6(46). PMID: 33188016    Free PMC article.
Oncolytic Viruses and Immune Checkpoint Inhibitors: Preclinical Developments to Clinical Trials.
June Kyu Hwang, JinWoo Hong, Chae-Ok Yun.
Int J Mol Sci, 2020 Nov 20; 21(22). PMID: 33207653    Free PMC article.
Outcomes based on prior therapy in the phase 3 METEOR trial of cabozantinib versus everolimus in advanced renal cell carcinoma.
Thomas Powles, Robert J Motzer, +15 authors, Daniel George.
Br J Cancer, 2018 Sep 11; 119(6). PMID: 30197417    Free PMC article.
Mechanisms of Resistance to Immune Checkpoint Blockade.
David Liu, Russell W Jenkins, Ryan J Sullivan.
Am J Clin Dermatol, 2018 Sep 28; 20(1). PMID: 30259383    Free PMC article.
Cancer immunotherapy: Moving beyond checkpoint inhibition.
Marianne Boes.
Oncotarget, 2018 Dec 20; 9(93). PMID: 30564293    Free PMC article.
Combining Radiotherapy and Immunotherapy in Lung Cancer: Can We Expect Limitations Due to Altered Normal Tissue Toxicity?
Florian Wirsdörfer, Simone de Leve, Verena Jendrossek.
Int J Mol Sci, 2018 Dec 24; 20(1). PMID: 30577587    Free PMC article.
The Interplay between Immunity and Microbiota at Intestinal Immunological Niche: The Case of Cancer.
Rossella Cianci, Laura Franza, +6 authors, Giovanni Cammarota.
Int J Mol Sci, 2019 Jan 27; 20(3). PMID: 30682772    Free PMC article.
First-in-class immune-modulating small molecule Icaritin in advanced hepatocellular carcinoma: preliminary results of safety, durable survival and immune biomarkers.
Ying Fan, Shu Li, +12 authors, Binghe Xu.
BMC Cancer, 2019 Mar 30; 19(1). PMID: 30922248    Free PMC article.
Natural Killer Immunotherapy for Minimal Residual Disease Eradication Following Allogeneic Hematopoietic Stem Cell Transplantation in Acute Myeloid Leukemia.
Norimichi Hattori, Tsuyoshi Nakamaki.
Int J Mol Sci, 2019 Apr 28; 20(9). PMID: 31027331    Free PMC article.
Drug repurposing to overcome resistance to various therapies for colorectal cancer.
Winnie Fong, Kenneth K W To.
Cell Mol Life Sci, 2019 May 16; 76(17). PMID: 31087119
Remarkable Alteration of PD-L1 Expression after Immune Checkpoint Therapy in Patients with Non-Small-Cell Lung Cancer: Two Autopsy Case Reports.
Toshiaki Takahashi, Akiko Tateishi, Andrey Bychkov, Junya Fukuoka.
Int J Mol Sci, 2019 May 28; 20(10). PMID: 31130676    Free PMC article.
A systems approach to clinical oncology uses deep phenotyping to deliver personalized care.
James T Yurkovich, Qiang Tian, Nathan D Price, Leroy Hood.
Nat Rev Clin Oncol, 2019 Oct 18; 17(3). PMID: 31619755
TMB: a promising immune-response biomarker, and potential spearhead in advancing targeted therapy trials.
Khalil Choucair, Susan Morand, +3 authors, John Nemunaitis.
Cancer Gene Ther, 2020 Apr 29; 27(12). PMID: 32341410
CRISPR-GEMM Pooled Mutagenic Screening Identifies KMT2D as a Major Modulator of Immune Checkpoint Blockade.
Guangchuan Wang, Ryan D Chow, +16 authors, Sidi Chen.
Cancer Discov, 2020 Sep 06; 10(12). PMID: 32887696    Free PMC article.
Evidences of CTLA-4 and PD-1 Blocking Agents-Induced Cardiotoxicity in Cellular and Preclinical Models.
Vincenzo Quagliariello, Margherita Passariello, +7 authors, Nicola Maurea.
J Pers Med, 2020 Oct 23; 10(4). PMID: 33086484    Free PMC article.
Cancer Immunotherapy Dosing: A Pharmacokinetic/Pharmacodynamic Perspective.
Félicien Le Louedec, Fanny Leenhardt, +3 authors, Joseph Ciccolini.
Vaccines (Basel), 2020 Nov 05; 8(4). PMID: 33142728    Free PMC article.
Engineering Prodrug Nanomedicine for Cancer Immunotherapy.
Bin Yang, Jing Gao, +2 authors, Haijun Yu.
Adv Sci (Weinh), 2020 Dec 12; 7(23). PMID: 33304763    Free PMC article.
Competitive glucose metabolism as a target to boost bladder cancer immunotherapy.
Julieta Afonso, Lúcio L Santos, Adhemar Longatto-Filho, Fátima Baltazar.
Nat Rev Urol, 2020 Jan 19; 17(2). PMID: 31953517
Regulation of PD-L1 Expression by NF-κB in Cancer.
Fabrizio Antonangeli, Ambra Natalini, +3 authors, Francesca Di Rosa.
Front Immunol, 2020 Dec 17; 11. PMID: 33324403    Free PMC article.
Beyond chemoradiotherapy: improving treatment outcomes for patients with stage III unresectable non-small-cell lung cancer through immuno-oncology and durvalumab (Imfinzi®▼, AstraZeneca UK Limited).
Priyanka Patel, Doraid Alrifai, +2 authors, AstraZeneca UK Limited.
Br J Cancer, 2020 Dec 10; 123(Suppl 1). PMID: 33293672    Free PMC article.
TGF-β Mediated Immune Evasion in Cancer-Spotlight on Cancer-Associated Fibroblasts.
Parisa Ghahremanifard, Ayan Chanda, Shirin Bonni, Pinaki Bose.
Cancers (Basel), 2020 Dec 10; 12(12). PMID: 33291370    Free PMC article.
Transcriptional Regulation of Cancer Immune Checkpoints: Emerging Strategies for Immunotherapy.
Simran Venkatraman, Jarek Meller, +2 authors, Somchai Chutipongtanate.
Vaccines (Basel), 2020 Dec 10; 8(4). PMID: 33291616    Free PMC article.
Primary and Acquired Resistance to Immunotherapy in Lung Cancer: Unveiling the Mechanisms Underlying of Immune Checkpoint Blockade Therapy.
Laura Boyero, Amparo Sánchez-Gastaldo, +3 authors, Reyes Bernabé-Caro.
Cancers (Basel), 2020 Dec 17; 12(12). PMID: 33322522    Free PMC article.
Epigenetic modulation of immunotherapy and implications in head and neck cancer.
Liye Zhou, Na Xu, +2 authors, Ravindra Uppaluri.
Cancer Metastasis Rev, 2021 Jan 07; 40(1). PMID: 33403469    Free PMC article.
Fcmr regulates mononuclear phagocyte control of anti-tumor immunity.
Shawn P Kubli, Larsen Vornholz, +14 authors, Tak W Mak.
Nat Commun, 2019 Jun 20; 10(1). PMID: 31213601    Free PMC article.
The Role of Antigen Processing and Presentation in Cancer and the Efficacy of Immune Checkpoint Inhibitor Immunotherapy.
Anastasia Mpakali, Efstratios Stratikos.
Cancers (Basel), 2021 Jan 08; 13(1). PMID: 33406696    Free PMC article.
Acquired Resistance to PD-1/PD-L1 Blockade in Lung Cancer: Mechanisms and Patterns of Failure.
Ranjan Pathak, Rebecca R Pharaon, +3 authors, Erminia Massarelli.
Cancers (Basel), 2021 Jan 10; 12(12). PMID: 33419311    Free PMC article.
Tumor-infiltrating mast cells are associated with resistance to anti-PD-1 therapy.
Rajasekharan Somasundaram, Thomas Connelly, +54 authors, Meenhard Herlyn.
Nat Commun, 2021 Jan 14; 12(1). PMID: 33436641    Free PMC article.
Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors.
Xingxing Hao, Louis D Falo Iii, +5 authors, Zhaoyang You.
J Immunother Cancer, 2021 Jan 08; 9(1). PMID: 33408093    Free PMC article.
Successful administration of sequential TVEC and pembrolizumab followed by Temozolomide in immunotherapy refractory intracranial metastatic melanoma with acquired B2M mutation.
Karam Khaddour, Joshua Dowling, +6 authors, George Ansstas.
Oncotarget, 2021 Jan 16; 11(52). PMID: 33447351    Free PMC article.
Role of Bladder Cancer Metabolic Reprogramming in the Effectiveness of Immunotherapy.
Mathijs P Scholtes, Florus C de Jong, Tahlita C M Zuiverloon, Dan Theodorescu.
Cancers (Basel), 2021 Jan 21; 13(2). PMID: 33466735    Free PMC article.
Mechanisms underlying low-clinical responses to PD-1/PD-L1 blocking antibodies in immunotherapy of cancer: a key role of exosomal PD-L1.
Zi Yin, Min Yu, +5 authors, Sheng Chen.
J Immunother Cancer, 2021 Jan 22; 9(1). PMID: 33472857    Free PMC article.
The Match between Molecular Subtypes, Histology and Microenvironment of Pancreatic Cancer and Its Relevance for Chemoresistance.
Javier Martinez-Useros, Mario Martin-Galan, Jesus Garcia-Foncillas.
Cancers (Basel), 2021 Jan 23; 13(2). PMID: 33477288    Free PMC article.
Metabolic crosstalk in the tumor microenvironment regulates antitumor immunosuppression and immunotherapy resisitance.
Fang Wei, Dan Wang, +10 authors, Zhaoyang Zeng.
Cell Mol Life Sci, 2020 Jul 13; 78(1). PMID: 32654036
Therapy-Induced Evolution of Human Lung Cancer Revealed by Single-Cell RNA Sequencing.
Ashley Maynard, Caroline E McCoach, +40 authors, Trever G Bivona.
Cell, 2020 Aug 22; 182(5). PMID: 32822576    Free PMC article.
[Research Progress on the Mechanism and Clinical Data of Cereblon 
in Reversing the Resistance of Lung Cancer to PD-1 Antibody by T cells].
Jingjing Guo, Di Mu, Ying Han.
Zhongguo Fei Ai Za Zhi, 2021 Jan 23; 24(1). PMID: 33478191    Free PMC article.
Make Your Cake and Eat It: Refueling of Immune Fitness in AML Post Allo-HCT Using Baking Soda.
Alex Tonks.
Immunometabolism, 2021 Feb 05; 3(1). PMID: 33537156    Free PMC article.
Preclinical Models of Pancreatic Ductal Adenocarcinoma and Their Utility in Immunotherapy Studies.
Thao N D Pham, Mario A Shields, +6 authors, Hidayatullah G Munshi.
Cancers (Basel), 2021 Jan 29; 13(3). PMID: 33503832    Free PMC article.
Tailoring precision immunotherapy: coming to a clinic soon?
Shuting Han, Wai Ho Shuen, +2 authors, Han Chong Toh.
ESMO Open, 2021 Feb 10; 5 Suppl 1. PMID: 33558033    Free PMC article.
B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies.
Zena N Willsmore, Robert J Harris, +21 authors, Sophia N Karagiannis.
Front Immunol, 2021 Feb 12; 11. PMID: 33569063    Free PMC article.
Standardization of pleural effusion-based tumor mutation burden (TMB) estimation using capture-based targeted sequencing.
Yongfeng Yu, Lan Shen, Wenxiang Ji, Shun Lu.
Ann Transl Med, 2021 Feb 12; 9(2). PMID: 33569442    Free PMC article.
Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy.
Ying Li, Yanni Cong, +10 authors, Shengdian Wang.
Nat Commun, 2021 Feb 13; 12(1). PMID: 33574265    Free PMC article.
Recent Advancements in the Mechanisms Underlying Resistance to PD-1/PD-L1 Blockade Immunotherapy.
Yu Yuan, Abdalla Adam, Chen Zhao, Honglei Chen.
Cancers (Basel), 2021 Feb 11; 13(4). PMID: 33562324    Free PMC article.
Immunomodulating nano-adaptors potentiate antibody-based cancer immunotherapy.
Cheng-Tao Jiang, Kai-Ge Chen, +11 authors, Jun Wang.
Nat Commun, 2021 Mar 03; 12(1). PMID: 33649336    Free PMC article.
Differential combination immunotherapy requirements for inflamed (warm) tumors versus T cell excluded (cool) tumors: engage, expand, enable, and evolve.
Kellsye P Fabian, Michelle R Padget, +2 authors, James W Hodge.
J Immunother Cancer, 2021 Feb 20; 9(2). PMID: 33602696    Free PMC article.
Cancer-on-a-Chip for Modeling Immune Checkpoint Inhibitor and Tumor Interactions.
Xing Jiang, Li Ren, +18 authors, Ali Khademhosseini.
Small, 2021 Jan 28; 17(7). PMID: 33502118    Free PMC article.
Long non-coding RNA TINCR suppresses metastatic melanoma dissemination by preventing ATF4 translation.
Marine Melixetian, Daniela Bossi, +11 authors, Luisa Lanfrancone.
EMBO Rep, 2021 Feb 16; 22(3). PMID: 33586907    Free PMC article.
Beyond PD-1: The Next Frontier for Immunotherapy in Melanoma.
Anjali Rohatgi, John M Kirkwood.
Front Oncol, 2021 Mar 19; 11. PMID: 33732652    Free PMC article.
A combination of PD‑1/PD‑L1 inhibitors: The prospect of overcoming the weakness of tumor immunotherapy (Review).
Xianbin Kong, Peng Lu, +8 authors, Jingyan Meng.
Mol Med Rep, 2021 Mar 25; 23(5). PMID: 33760188    Free PMC article.
MITF induces escape from innate immunity in melanoma.
Luis Sánchez-Del-Campo, Román Martí-Díaz, +7 authors, José Neptuno Rodríguez-López.
J Exp Clin Cancer Res, 2021 Apr 02; 40(1). PMID: 33789714    Free PMC article.
Liposomal Delivery of Mitoxantrone and a Cholesteryl Indoximod Prodrug Provides Effective Chemo-immunotherapy in Multiple Solid Tumors.
Kuo-Ching Mei, Yu-Pei Liao, +14 authors, Andre E Nel.
ACS Nano, 2020 Sep 18; 14(10). PMID: 32940463    Free PMC article.
Adoptive T Cell Therapy Is Complemented by Oncolytic Virotherapy with Fusogenic VSV-NDV in Combination Treatment of Murine Melanoma.
Teresa Krabbe, Janina Marek, +4 authors, Jennifer Altomonte.
Cancers (Basel), 2021 Apr 04; 13(5). PMID: 33801359    Free PMC article.
The Evolving Immunotherapy Landscape and the Epidemiology, Diagnosis, and Management of Cardiotoxicity: JACC: CardioOncology Primer.
Lili Zhang, Kerry L Reynolds, +2 authors, Tomas G Neilan.
JACC CardioOncol, 2021 Apr 13; 3(1). PMID: 33842895    Free PMC article.
A prime/boost vaccine platform efficiently identifies CD27 agonism and depletion of myeloid-derived suppressor cells as therapies that rationally combine with checkpoint blockade in ovarian cancer.
A J R McGray, C Eppolito, +9 authors, K Odunsi.
Cancer Immunol Immunother, 2021 Apr 22; 70(12). PMID: 33880648    Free PMC article.
Recent Advances to Augment NK Cell Cancer Immunotherapy Using Nanoparticles.
Kwang-Soo Kim, Dong-Hwan Kim, Dong-Hyun Kim.
Pharmaceutics, 2021 May 01; 13(4). PMID: 33918941    Free PMC article.
Combination Therapy of Novel Oncolytic Adenovirus with Anti-PD1 Resulted in Enhanced Anti-Cancer Effect in Syngeneic Immunocompetent Melanoma Mouse Model.
Mariangela Garofalo, Laura Bertinato, +6 authors, Lukasz Kuryk.
Pharmaceutics, 2021 May 01; 13(4). PMID: 33919827    Free PMC article.
The 2018 Nobel Prize in Medicine for breakthroughs in targeting immune checkpoint inhibitors: a brief perspective.
Adan Rios, Georgina To'a Salazar, Ningyan Zhang, Zhiqiang An.
Antib Ther, 2019 Mar 14; 2(1). PMID: 33928220    Free PMC article.
Pyroptosis: a new paradigm of cell death for fighting against cancer.
Yixin Tan, Quanzhu Chen, +7 authors, Mei Yi.
J Exp Clin Cancer Res, 2021 May 05; 40(1). PMID: 33941231    Free PMC article.
Modulating innate immune activation states impacts the efficacy of specific Aβ immunotherapy.
Yona Levites, Cory Funk, +16 authors, Todd E Golde.
Mol Neurodegener, 2021 May 08; 16(1). PMID: 33957936    Free PMC article.
Targeted Therapy Given after Anti-PD-1 Leads to Prolonged Responses in Mouse Melanoma Models through Sustained Antitumor Immunity.
Manali S Phadke, Zhihua Chen, +17 authors, Keiran S M Smalley.
Cancer Immunol Res, 2021 Mar 04; 9(5). PMID: 33653716    Free PMC article.
Identification of an immune classification for cervical cancer and integrative analysis of multiomics data.
Xintong Lyu, Guang Li, Qiao Qiao.
J Transl Med, 2021 May 12; 19(1). PMID: 33971902    Free PMC article.
The Dynamic Entropy of Tumor Immune Infiltrates: The Impact of Recirculation, Antigen-Specific Interactions, and Retention on T Cells in Tumors.
Tiffany C Blair, Alejandro F Alice, +2 authors, Michael J Gough.
Front Oncol, 2021 May 11; 11. PMID: 33968757    Free PMC article.
Pembrolizumab in unresectable or metastatic MSI-high colorectal cancer: safety and efficacy.
Marc T Roth, Satya Das.
Expert Rev Anticancer Ther, 2020 Nov 14; 21(2). PMID: 33183114    Free PMC article.
Advances in Targeting Cutaneous Melanoma.
Dimitri Kasakovski, Marina Skrygan, Thilo Gambichler, Laura Susok.
Cancers (Basel), 2021 May 01; 13(9). PMID: 33925915    Free PMC article.
Real-World Survival in Patients with Metastatic Melanoma after Discontinuation of Anti-PD-1 Immunotherapy for Objective Response or Adverse Effects: A Retrospective Study.
Julie Valentin, Thomas Ferté, +6 authors, Emilie Gérard.
J Oncol, 2021 May 18; 2021. PMID: 33995528    Free PMC article.
Targeting PIM1-Mediated Metabolism in Myeloid Suppressor Cells to Treat Cancer.
Gang Xin, Yao Chen, +11 authors, Weiguo Cui.
Cancer Immunol Res, 2021 Feb 14; 9(4). PMID: 33579728    Free PMC article.
Novel Pharmacological Options in the Treatment of Cholangiocarcinoma: Mechanisms of Resistance.
Jose J G Marin, Paula Sanchon-Sanchez, +4 authors, Rocio I R Macias.
Cancers (Basel), 2021 Jun 03; 13(10). PMID: 34068398    Free PMC article.
T-cell response to phytohemagglutinin in the interferon-γ release assay as a potential biomarker for the response to immune checkpoint inhibitors in patients with non-small cell lung cancer.
Chisato Kamimaki, Nobuaki Kobayashi, +12 authors, Takeshi Kaneko.
Thorac Cancer, 2021 May 05; 12(11). PMID: 33943031    Free PMC article.
Clinical Perspectives to Overcome Acquired Resistance to Anti-Programmed Death-1 and Anti-Programmed Death Ligand-1 Therapy in Non-Small Cell Lung Cancer.
Yong Jun Lee, Jii Bum Lee, Sang-Jun Ha, Hye Ryun Kim.
Mol Cells, 2021 May 19; 44(5). PMID: 34001680    Free PMC article.
Artificial Nanoscale Erythrocytes from Clinically Relevant Compounds for Enhancing Cancer Immunotherapy.
Wenquan Ou, Kang Sik Nam, +5 authors, Jeong Hoon Byeon.
Nanomicro Lett, 2020 Apr 13; 12(1). PMID: 34138119    Free PMC article.
Recent Advancements in Nanomedicine for 'Cold' Tumor Immunotherapy.
Qinjun Chen, Tao Sun, Chen Jiang.
Nanomicro Lett, 2021 Jun 18; 13(1). PMID: 34138315    Free PMC article.
Critical role of the CD44lowCD62Llow CD8+ T cell subset in restoring antitumor immunity in aged mice.
Yuka Nakajima, Kenji Chamoto, Takuma Oura, Tasuku Honjo.
Proc Natl Acad Sci U S A, 2021 Jun 06; 118(23). PMID: 34088845    Free PMC article.
Acquired Resistance to Immune Checkpoint Blockades: The Underlying Mechanisms and Potential Strategies.
Binghan Zhou, Yuan Gao, Peng Zhang, Qian Chu.
Front Immunol, 2021 Jul 02; 12. PMID: 34194441    Free PMC article.
The mechanisms of action of Plasmodium infection against cancer.
Xiaoping Chen, Li Qin, Wen Hu, Dickson Adah.
Cell Commun Signal, 2021 Jul 11; 19(1). PMID: 34243757    Free PMC article.
Reactivation of the tumor suppressor PTEN by mRNA nanoparticles enhances antitumor immunity in preclinical models.
Yao-Xin Lin, Yi Wang, +10 authors, Jinjun Shi.
Sci Transl Med, 2021 Jun 25; 13(599). PMID: 34162754    Free PMC article.
The Tumor Microenvironment Factors That Promote Resistance to Immune Checkpoint Blockade Therapy.
Bonnie L Russell, Selisha A Sooklal, +2 authors, Monde Ntwasa.
Front Oncol, 2021 Jul 17; 11. PMID: 34268109    Free PMC article.
Enriching CCL3 in the Tumor Microenvironment Facilitates T cell Responses and Improves the Efficacy of Anti-PD-1 Therapy.
Tae Gun Kang, Hyo Jin Park, +2 authors, Sang-Jun Ha.
Immune Netw, 2021 Jul 20; 21(3). PMID: 34277113    Free PMC article.
Hyperprogressive Disease in Cancers Treated With Immune Checkpoint Inhibitors.
Pan Shen, Liang Han, +2 authors, Shenghao Tu.
Front Pharmacol, 2021 Jul 23; 12. PMID: 34290608    Free PMC article.
Telomerase as a Target for Therapeutic Cancer Vaccines and Considerations for Optimizing Their Clinical Potential.
Espen Basmo Ellingsen, Sara M Mangsbo, Eivind Hovig, Gustav Gaudernack.
Front Immunol, 2021 Jul 23; 12. PMID: 34290704    Free PMC article.
A narrative review of combined stereotactic ablative radiotherapy and immunotherapy in metastatic non-small cell lung cancer.
Zarique Z Akanda, Paul J Neeson, +5 authors, Shankar Siva.
Transl Lung Cancer Res, 2021 Jul 24; 10(6). PMID: 34295676    Free PMC article.
Enhancing Checkpoint Inhibitor Therapy in Solid Tissue Cancers: The Role of Diet, the Microbiome & Microbiome-Derived Metabolites.
Agnieszka Beata Malczewski, Natkunam Ketheesan, Jermaine I G Coward, Severine Navarro.
Front Immunol, 2021 Jul 27; 12. PMID: 34305883    Free PMC article.
Systematic Analysis of the Oncogenic Role of WDR62 in Human Tumors.
Yulan Bu, Lihua Zhang, +3 authors, Jiaqiu Li.
Dis Markers, 2021 Jul 27; 2021. PMID: 34306258    Free PMC article.
Targeted Glucose or Glutamine Metabolic Therapy Combined With PD-1/PD-L1 Checkpoint Blockade Immunotherapy for the Treatment of Tumors - Mechanisms and Strategies.
Guofeng Ma, Chun Li, +8 authors, Haitao Niu.
Front Oncol, 2021 Jul 31; 11. PMID: 34327138    Free PMC article.
Tumor microenvironment and immune evasion in head and neck squamous cell carcinoma.
Areeg Elmusrati, Justin Wang, Cun-Yu Wang.
Int J Oral Sci, 2021 Aug 04; 13(1). PMID: 34341329    Free PMC article.
Cancer Immunotherapies: From Efficacy to Resistance Mechanisms - Not Only Checkpoint Matters.
Shuyue Wang, Kun Xie, Tengfei Liu.
Front Immunol, 2021 Aug 10; 12. PMID: 34367148    Free PMC article.
Musculoskeletal adverse reactions after immunotherapy for cancer: A case series.
Ioana Creţu, Mihai Bojincă, +7 authors, Ruxandra Ionescu.
Exp Ther Med, 2021 Aug 11; 22(3). PMID: 34373713    Free PMC article.
Transfer learning between preclinical models and human tumors identifies a conserved NK cell activation signature in anti-CTLA-4 responsive tumors.
Emily F Davis-Marcisak, Allison A Fitzgerald, +5 authors, Elana J Fertig.
Genome Med, 2021 Aug 12; 13(1). PMID: 34376232    Free PMC article.
Adoptive cellular therapy in solid tumor malignancies: review of the literature and challenges ahead.
Kedar Kirtane, Hany Elmariah, Christine H Chung, Daniel Abate-Daga.
J Immunother Cancer, 2021 Jul 25; 9(7). PMID: 34301811    Free PMC article.
Search for effective treatments in patients with advanced refractory melanoma continues: can novel intratumoral therapies deliver?
Yana G Najjar.
J Immunother Cancer, 2021 Jul 28; 9(7). PMID: 34312244    Free PMC article.
Modified Glasgow Prognostic Score associated with survival in metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Jacqueline T Brown, Yuan Liu, +15 authors, Mehmet Asim Bilen.
J Immunother Cancer, 2021 Jul 31; 9(7). PMID: 34326170    Free PMC article.
Targeting MDSC for Immune-Checkpoint Blockade in Cancer Immunotherapy: Current Progress and New Prospects.
Tianhang Li, Tianyao Liu, +5 authors, Rong Yang.
Clin Med Insights Oncol, 2021 Aug 20; 15. PMID: 34408525    Free PMC article.
Nanotechnology-based immunotherapies to combat cancer metastasis.
Yuping Zhao, Muhammad Bilal, +3 authors, Hafiz M N Iqbal.
Mol Biol Rep, 2021 Aug 24; 48(9). PMID: 34424444
Failure of Immunotherapy-The Molecular and Immunological Origin of Immunotherapy Resistance in Lung Cancer.
Justyna Błach, Kamila Wojas-Krawczyk, Marcin Nicoś, Paweł Krawczyk.
Int J Mol Sci, 2021 Aug 28; 22(16). PMID: 34445735    Free PMC article.
Generation of avian-derived anti-B7-H4 antibodies exerts a blockade effect on the immunosuppressive response.
Tsai-Yu Lin, Tsung-Hsun Tsai, +8 authors, Yu-Ching Lee.
Exp Anim, 2021 Mar 16; 70(3). PMID: 33716253    Free PMC article.
Cancer and the Microbiome-Influence of the Commensal Microbiota on Cancer, Immune Responses, and Immunotherapy.
Vyara Matson, Carolina Soto Chervin, Thomas F Gajewski.
Gastroenterology, 2020 Dec 01; 160(2). PMID: 33253684    Free PMC article.
Tumor microenvironment is not an 'innocent bystander' in the resistance to treatment of head and neck cancers (Review).
Laura Mazilu, Andra-Iulia Suceveanu, +3 authors, Serban-Mircea Negru.
Exp Ther Med, 2021 Sep 02; 22(4). PMID: 34466142    Free PMC article.
The future of microfluidics in immune checkpoint blockade.
Jonathan Briones, Wilfred Espulgar, +3 authors, Masato Saito.
Cancer Gene Ther, 2020 Oct 29; 28(9). PMID: 33110208
Telomere Shortening in Peripheral Leukocytes Is Associated With Poor Survival in Cancer Patients Treated With Immune Checkpoint Inhibitor Therapy.
Benjamin Rolles, Joao Gorgulho, +10 authors, Sven H Loosen.
Front Oncol, 2021 Sep 08; 11. PMID: 34490122    Free PMC article.
Clinical Significance and Immunologic Landscape of a Five-IL(R)-Based Signature in Lung Adenocarcinoma.
Tao Fan, Shize Pan, +4 authors, Qing Geng.
Front Immunol, 2021 Sep 10; 12. PMID: 34497605    Free PMC article.
A Novel Oral Arginase 1/2 Inhibitor Enhances the Antitumor Effect of PD-1 Inhibition in Murine Experimental Gliomas by Altering the Immunosuppressive Environment.
Paulina Pilanc, Kamil Wojnicki, +9 authors, Bozena Kaminska.
Front Oncol, 2021 Sep 11; 11. PMID: 34504786    Free PMC article.
The CD112R/CD112 axis: a breakthrough in cancer immunotherapy.
Taofei Zeng, Yuqing Cao, +3 authors, Feng Xu.
J Exp Clin Cancer Res, 2021 Sep 12; 40(1). PMID: 34507594    Free PMC article.
Strategies to Overcome Failures in T-Cell Immunotherapies by Targeting PI3K-δ and -γ.
Sanjay Chandrasekaran, Christopher Ronald Funk, +3 authors, Edmund K Waller.
Front Immunol, 2021 Sep 14; 12. PMID: 34512641    Free PMC article.
Immunotherapeutic Strategies for Canine Lymphoma: Changing the Odds Against Non-Hodgkin Lymphoma.
Joana N R Dias, Ana S André, +3 authors, Frederico Aires-da-Silva.
Front Vet Sci, 2021 Sep 14; 8. PMID: 34513964    Free PMC article.
Fibrinogen-like protein 1 (FGL1): the next immune checkpoint target.
Wenjing Qian, Mingfang Zhao, Ruoyu Wang, Heming Li.
J Hematol Oncol, 2021 Sep 17; 14(1). PMID: 34526102    Free PMC article.
Emerging therapeutic opportunities for integrin inhibitors.
R J Slack, S J F Macdonald, +2 authors, R J D Hatley.
Nat Rev Drug Discov, 2021 Sep 19; 21(1). PMID: 34535788    Free PMC article.
Faecal microbiota transplantation enhances efficacy of immune checkpoint inhibitors therapy against cancer.
Yong-Bo Kang, Yue Cai.
World J Gastroenterol, 2021 Sep 21; 27(32). PMID: 34539138    Free PMC article.
Relapsed and refractory classical Hodgkin lymphoma: could virotherapy help solve the equation?
Selma Addou, Clémentine Sarkozy, +6 authors, Jean-Marie Michot.
Hum Vaccin Immunother, 2021 Jun 09; 17(10). PMID: 34101538    Free PMC article.
The Yin and Yang of Type I IFNs in Cancer Promotion and Immune Activation.
Martina Musella, Claudia Galassi, Nicoletta Manduca, Antonella Sistigu.
Biology (Basel), 2021 Sep 29; 10(9). PMID: 34571733    Free PMC article.
Epitranscriptomic Approach: To Improve the Efficacy of ICB Therapy by Co-Targeting Intracellular Checkpoint CISH.
Sunil Kumar, Parth Sarthi, +4 authors, Yong-Soo Bae.
Cells, 2021 Sep 29; 10(9). PMID: 34571899    Free PMC article.
Inhibiting the Unconventionals: Importance of Immune Checkpoint Receptors in γδ T, MAIT, and NKT Cells.
Elisa Catafal-Tardos, Maria Virginia Baglioni, Vasileios Bekiaris.
Cancers (Basel), 2021 Sep 29; 13(18). PMID: 34572874    Free PMC article.
Combining Photodynamic Therapy with Immunostimulatory Nanoparticles Elicits Effective Anti-Tumor Immune Responses in Preclinical Murine Models.
Ruben Victor Huis In 't Veld, Candido G Da Silva, +2 authors, Ferry Ossendorp.
Pharmaceutics, 2021 Sep 29; 13(9). PMID: 34575546    Free PMC article.
Nanoparticles Targeting Innate Immune Cells in Tumor Microenvironment.
Hochung Jang, Eun Hye Kim, +2 authors, Yoosoo Yang.
Int J Mol Sci, 2021 Sep 29; 22(18). PMID: 34576180    Free PMC article.
Short Review on Advances in Hydrogel-Based Drug Delivery Strategies for Cancer Immunotherapy.
Hee Seung Seo, Chi-Pin James Wang, Wooram Park, Chun Gwon Park.
Tissue Eng Regen Med, 2021 Oct 02; 19(2). PMID: 34596839    Free PMC article.
Molecular predictors of response to pembrolizumab in thymic carcinoma.
Yongfeng He, Archana Ramesh, +2 authors, Giuseppe Giaccone.
Cell Rep Med, 2021 Oct 09; 2(9). PMID: 34622229    Free PMC article.
Antiangiogenic antibody BD0801 combined with immune checkpoint inhibitors achieves synergistic antitumor activity and affects the tumor microenvironment.
Liting Xue, Xingyuan Gao, +9 authors, Wenqing Yang.
BMC Cancer, 2021 Oct 24; 21(1). PMID: 34686154    Free PMC article.
Immune Profiling of Medullary Thyroid Cancer-An Opportunity for Immunotherapy.
Kinga Hińcza-Nowak, Artur Kowalik, +7 authors, Aldona Kowalska.
Genes (Basel), 2021 Oct 24; 12(10). PMID: 34680929    Free PMC article.
LncRNAs in the Regulation of Genes and Signaling Pathways through miRNA-Mediated and Other Mechanisms in Clear Cell Renal Cell Carcinoma.
Eleonora A Braga, Marina V Fridman, +6 authors, Sergey G Morozov.
Int J Mol Sci, 2021 Oct 24; 22(20). PMID: 34681854    Free PMC article.
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab.
Paul B Chapman, Vetri Sudar Jayaprakasam, +5 authors, Allison Betof Warner.
J Immunother Cancer, 2021 Oct 28; 9(10). PMID: 34702752    Free PMC article.
Emerging combination immunotherapy strategies for breast cancer: dual immune checkpoint modulation, antibody-drug conjugates and bispecific antibodies.
Evanthia T Roussos Torres, Leisha A Emens.
Breast Cancer Res Treat, 2021 Oct 31; 191(2). PMID: 34716871
Lung microbiota: Unexploited treasure hidden in the immune microenvironment of lung cancer.
Ruifeng Shi, Yongwen Li, Hongyu Liu, Jun Chen.
Thorac Cancer, 2021 Sep 23; 12(21). PMID: 34549526    Free PMC article.
Environmental eustress modulates β-ARs/CCL2 axis to induce anti-tumor immunity and sensitize immunotherapy against liver cancer in mice.
Chaobao Liu, Yang Yang, +8 authors, Hui Wang.
Nat Commun, 2021 Oct 02; 12(1). PMID: 34593796    Free PMC article.
Angiogenesis Pathway in Kidney Renal Clear Cell Carcinoma and Its Prognostic Value for Cancer Risk Prediction.
Xiangyu Che, Wenyan Su, +3 authors, Guangzhen Wu.
Front Med (Lausanne), 2021 Nov 16; 8. PMID: 34778292    Free PMC article.
IL-10 Signaling Elicited by Nivolumab-Induced Activation of the MAP Kinase Pathway Does Not Fully Contribute to Nivolumab-Modulated Heterogeneous T Cell Responses.
Taylor A Harper, Silvia M Bacot, +10 authors, Gerald M Feldman.
Int J Mol Sci, 2021 Nov 14; 22(21). PMID: 34769278    Free PMC article.
Individualized Proteogenomics Reveals the Mutational Landscape of Melanoma Patients in Response to Immunotherapy.
Marisa Schmitt, Tobias Sinnberg, +4 authors, Nicolas C Nalpas.
Cancers (Basel), 2021 Nov 14; 13(21). PMID: 34771574    Free PMC article.
Proteogenomics Reveals Perturbed Signaling Networks in Malignant Melanoma Cells Resistant to BRAF Inhibition.
Marisa Schmitt, Tobias Sinnberg, +4 authors, Nicolas C Nalpas.
Mol Cell Proteomics, 2021 Oct 22; 20. PMID: 34673281    Free PMC article.
Targeted Therapies in Cancer: To Be or Not to Be, Selective.
Skye Montoya, Deborah Soong, +3 authors, Justin Taylor.
Biomedicines, 2021 Nov 28; 9(11). PMID: 34829820    Free PMC article.
Early prediction of clinical response to checkpoint inhibitor therapy in human solid tumors through mathematical modeling.
Joseph D Butner, Geoffrey V Martin, +18 authors, Vittorio Cristini.
Elife, 2021 Nov 10; 10. PMID: 34749885    Free PMC article.
Going with the Flow: Modeling the Tumor Microenvironment Using Microfluidic Technology.
Hongyan Xie, Jackson W Appelt, Russell W Jenkins.
Cancers (Basel), 2021 Dec 11; 13(23). PMID: 34885161    Free PMC article.
Applying artificial intelligence for cancer immunotherapy.
Zhijie Xu, Xiang Wang, +3 authors, Zhicheng Gong.
Acta Pharm Sin B, 2021 Dec 14; 11(11). PMID: 34900525    Free PMC article.
Virus-inspired strategies for cancer therapy.
Xiao Yin Ma, Brett D Hill, Trang Hoang, Fei Wen.
Semin Cancer Biol, 2021 Jun 29;. PMID: 34182141    Free PMC article.
Integrin αE(CD103)β7 in Epithelial Cancer.
Johanna C Hoffmann, Michael P Schön.
Cancers (Basel), 2021 Dec 25; 13(24). PMID: 34944831    Free PMC article.
Can Immune Suppression and Epigenome Regulation in Placenta Offer Novel Insights into Cancer Immune Evasion and Immunotherapy Resistance?
Sultana Mehbuba Hossain, Chiemi F Lynch-Sutherland, +2 authors, Michael R Eccles.
Epigenomes, 2021 Dec 31; 5(3). PMID: 34968365    Free PMC article.
Nintedanib enhances the efficacy of PD-L1 blockade by upregulating MHC-I and PD-L1 expression in tumor cells.
Jingyao Tu, Haoran Xu, +7 authors, Xianglin Yuan.
Theranostics, 2022 Jan 04; 12(2). PMID: 34976211    Free PMC article.
Combination therapy with immune checkpoint inhibitors (ICIs); a new frontier.
Somayeh Vafaei, Angelina O Zekiy, +4 authors, Majid Zamani.
Cancer Cell Int, 2022 Jan 05; 22(1). PMID: 34980128    Free PMC article.
Early disappearance of tumor antigen-reactive T cells from peripheral blood correlates with superior clinical outcomes in melanoma under anti-PD-1 therapy.
Jonas Bochem, Henning Zelba, +20 authors, Kilian Wistuba-Hamprecht.
J Immunother Cancer, 2021 Dec 23; 9(12). PMID: 34933966    Free PMC article.
A Novel Kinase Inhibitor AX-0085 Inhibits Interferon-γ-Mediated Induction of PD-L1 Expression and Promotes Immune Reaction to Lung Adenocarcinoma Cells.
Jusong Kim, Haeyeon Jang, +9 authors, Jaesang Kim.
Cells, 2022 Jan 12; 11(1). PMID: 35011581    Free PMC article.
Modulation of intrinsic inhibitory checkpoints using nano-carriers to unleash NK cell activity.
Guy Biber, Batel Sabag, +7 authors, Mira Barda-Saad.
EMBO Mol Med, 2021 Nov 03; 14(1). PMID: 34725941    Free PMC article.
Immune modulation underpins the anti-cancer activity of HDAC inhibitors.
Wiktoria Blaszczak, Geng Liu, +7 authors, Nicholas B La Thangue.
Mol Oncol, 2021 Mar 28; 15(12). PMID: 33773029    Free PMC article.
Long Non-Coding RNAs in Lung Cancer: The Role in Tumor Microenvironment.
Shuang Dai, Ting Liu, +5 authors, Feng Luo.
Front Cell Dev Biol, 2022 Jan 21; 9. PMID: 35047506    Free PMC article.
Biomarkers for predicting the efficacy of immune checkpoint inhibitors.
Chengji Wang, He-Nan Wang, Liang Wang.
J Cancer, 2022 Jan 25; 13(2). PMID: 35069896    Free PMC article.
Rheumatological Adverse Events Following Immunotherapy for Cancer.
Ioana Cretu, Bogdan Cretu, +4 authors, Ruxandra Ionescu.
Medicina (Kaunas), 2022 Jan 22; 58(1). PMID: 35056402    Free PMC article.
Local therapy with an engineered oncolytic adenovirus enables antitumor response in non-injected melanoma tumors in mice treated with aPD-1.
Dafne C A Quixabeira, Victor Cervera-Carrascon, +9 authors, Akseli Hemminki.
Oncoimmunology, 2022 Jan 28; 11(1). PMID: 35083096    Free PMC article.
Genomics-guided pre-clinical development of cancer therapies.
Hayley E Francies, Ultan McDermott, Mathew J Garnett.
Nat Cancer, 2020 May 01; 1(5). PMID: 35121986
MALAT-1/p53/miR-155/miR-146a ceRNA circuit tuned by methoxylated quercitin glycoside alters immunogenic and oncogenic profiles of breast cancer.
Mustafa Abdel-Latif, Ahmed Riad, +5 authors, Rana A Youness.
Mol Cell Biochem, 2022 Feb 08; 477(4). PMID: 35129780
Novel technologies in cfDNA analysis and potential utility in clinic.
Jie Li, Mengyue Xu, +4 authors, Xun Lan.
Chin J Cancer Res, 2022 Feb 08; 33(6). PMID: 35125814    Free PMC article.
Immunotherapies for hepatocellular carcinoma.
Justin K H Liu, Andrew F Irvine, Rebecca L Jones, Adel Samson.
Cancer Med, 2021 Dec 26; 11(3). PMID: 34953051    Free PMC article.
Rexinoids Modulate Effector T Cell Expression of Mucosal Homing Markers CCR9 and α4β7 Integrin and Direct Their Migration In Vitro.
Kavita R Manhas, Pamela A Marshall, +4 authors, Joseph N Blattman.
Front Immunol, 2022 Feb 15; 13. PMID: 35154092    Free PMC article.
Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity.
Adrià Archilla-Ortega, Carla Domuro, Juan Martin-Liberal, Purificación Muñoz.
J Exp Clin Cancer Res, 2022 Feb 16; 41(1). PMID: 35164813    Free PMC article.
Mitochondrial Fus1/Tusc2 and cellular Ca2+ homeostasis: tumor suppressor, anti-inflammatory and anti-aging implications.
Roman Uzhachenko, Akiko Shimamoto, +3 authors, Anil Shanker.
Cancer Gene Ther, 2022 Feb 20;. PMID: 35181743
T Lymphocyte Infiltration in Association with IDO1 Expression in Resected Lung Adenocarcinoma and Normal Adjacent Lung Tissues.
Xiaoling Zhao, Yaran Li, +8 authors, Dengxiang Liu.
Biomed Res Int, 2022 Feb 22; 2022. PMID: 35187162    Free PMC article.
Next steps for clinical translation of adenosine pathway inhibition in cancer immunotherapy.
Ryan C Augustin, Robert D Leone, +3 authors, Jason J Luke.
J Immunother Cancer, 2022 Feb 10; 10(2). PMID: 35135866    Free PMC article.
Assessment of Capecitabine and Bevacizumab With or Without Atezolizumab for the Treatment of Refractory Metastatic Colorectal Cancer: A Randomized Clinical Trial.
Niharika B Mettu, Fang-Shu Ou, +13 authors, Tanios Bekaii-Saab.
JAMA Netw Open, 2022 Feb 19; 5(2). PMID: 35179586    Free PMC article.
Proteolysis-Targeting Chimera (PROTAC): Is the Technology Looking at the Treatment of Brain Tumors?
Ludovica Lospinoso Severini, Francesca Bufalieri, Paola Infante, Lucia Di Marcotullio.
Front Cell Dev Biol, 2022 Mar 05; 10. PMID: 35242765    Free PMC article.
Epitope Spreading and the Efficacy of Immune Checkpoint Inhibition in Cancer.
W Robert Liu, David E Fisher.
Int J Oncol Res, 2021 Jan 01; 4(1). PMID: 35243349    Free PMC article.
Phase IB study of ziv-aflibercept plus pembrolizumab in patients with advanced solid tumors.
Osama E Rahma, Kevin Tyan, +11 authors, F Stephen Hodi.
J Immunother Cancer, 2022 Mar 11; 10(3). PMID: 35264434    Free PMC article.
Inhibition of Cyclin Dependent Kinase 4/6 Overcomes Primary Resistance to Programmed Cell Death 1 Blockade in Malignant Mesothelioma.
Hee-Jin Jang, Cynthia Y Truong, +9 authors, Hyun-Sung Lee.
Ann Thorac Surg, 2021 Oct 01;. PMID: 34592265    Free PMC article.
Identification of New Vulnerabilities in Conjunctival Melanoma Using Image-Based High Content Drug Screening.
Katya Nardou, Michael Nicolas, +8 authors, Alexandre Pierre Moulin.
Cancers (Basel), 2022 Mar 26; 14(6). PMID: 35326726    Free PMC article.
Targeting DNA Damage Response and Immune Checkpoint for Anticancer Therapy.
Jau-Ling Huang, Yu-Tzu Chang, Zhen-Yang Hong, Chang-Shen Lin.
Int J Mol Sci, 2022 Mar 26; 23(6). PMID: 35328658    Free PMC article.
Adenovirus Encoding Tumor Necrosis Factor Alpha and Interleukin 2 Induces a Tertiary Lymphoid Structure Signature in Immune Checkpoint Inhibitor Refractory Head and Neck Cancer.
James H A Clubb, Tatiana V Kudling, +14 authors, Akseli Hemminki.
Front Immunol, 2022 Apr 01; 13. PMID: 35355980    Free PMC article.
IDO1 Inhibition Reduces Immune Cell Exclusion Through Inducing Cell Migration While PD-1 Blockage Increases IL-6 and -8 Secretion From T Cells in Head and Neck Cancer.
Meri Sieviläinen, Jordan Saavalainen, +2 authors, Ahmed Al-Samadi.
Front Immunol, 2022 Apr 02; 13. PMID: 35359980    Free PMC article.
The engineered CD80 variant fusion therapeutic davoceticept combines checkpoint antagonism with conditional CD28 costimulation for anti-tumor immunity.
Mark F Maurer, Katherine E Lewis, +17 authors, Stanford L Peng.
Nat Commun, 2022 Apr 06; 13(1). PMID: 35379805    Free PMC article.
Tumor immunotherapies by immune checkpoint inhibitors (ICIs); the pros and cons.
Adel Naimi, Rebar N Mohammed, +11 authors, Ehsan Razeghian.
Cell Commun Signal, 2022 Apr 09; 20(1). PMID: 35392976    Free PMC article.
Immune checkpoint blockade sensitivity and progression-free survival associates with baseline CD8+ T cell clone size and cytotoxicity.
Robert A Watson, Orion Tong, +8 authors, Benjamin P Fairfax.
Sci Immunol, 2021 Oct 02; 6(64). PMID: 34597125    Free PMC article.
Single-Cell Profiling Reveals Heterogeneity of Primary and Lymph Node Metastatic Tumors and Immune Cell Populations and Discovers Important Prognostic Significance of CCDC43 in Oral Squamous Cell Carcinoma.
Zhenyu Wang, Hongbo Zhang, +3 authors, Muying Ying.
Front Immunol, 2022 Apr 12; 13. PMID: 35401551    Free PMC article.
A machine learning algorithm with subclonal sensitivity reveals widespread pan-cancer human leukocyte antigen loss of heterozygosity.
Rachel Marty Pyke, Dattatreya Mellacheruvu, +10 authors, Sean Michael Boyle.
Nat Commun, 2022 Apr 14; 13(1). PMID: 35414054    Free PMC article.
A tumor-specific pro-IL-12 activates preexisting cytotoxic T cells to control established tumors.
Diyuan Xue, Benjamin Moon, +7 authors, Hua Peng.
Sci Immunol, 2022 Jan 08; 7(67). PMID: 34995098    Free PMC article.
Splenic and PB immune recovery in neoadjuvant treated gastrointestinal cancer patients.
Kathryn E Cole, Quan P Ly, +6 authors, James E Talmadge.
Int Immunopharmacol, 2022 Feb 25; 106. PMID: 35203041    Free PMC article.
The Evolution of Immune Checkpoint Inhibitors in Advanced Urothelial Carcinoma.
Hélène Houssiau, Emmanuel Seront.
Cancers (Basel), 2022 Apr 13; 14(7). PMID: 35406412    Free PMC article.
Immunotherapy for Cervical Cancer: Are We Ready for Prime Time?
Margherita Turinetto, Anna A Valsecchi, +3 authors, Giorgio Valabrega.
Int J Mol Sci, 2022 Apr 13; 23(7). PMID: 35408919    Free PMC article.
Targeting non-coding RNAs to overcome cancer therapy resistance.
BaoQing Chen, Mihnea P Dragomir, +3 authors, George A Calin.
Signal Transduct Target Ther, 2022 Apr 15; 7(1). PMID: 35418578    Free PMC article.
Cell Communication Network factor 4 promotes tumor-induced immunosuppression in melanoma.
Audry Fernandez, Wentao Deng, +4 authors, David J Klinke.
EMBO Rep, 2022 Feb 01; 23(4). PMID: 35099839    Free PMC article.
Patterns of Peripheral Blood B-Cell Subtypes Are Associated With Treatment Response in Patients Treated With Immune Checkpoint Inhibitors: A Prospective Longitudinal Pan-Cancer Study.
Dominik A Barth, Stefanie Stanzer, +15 authors, Martin Pichler.
Front Immunol, 2022 Apr 19; 13. PMID: 35432362    Free PMC article.
Understanding Drug Sensitivity and Tackling Resistance in Cancer.
Jeffrey W Tyner, Franziska Haderk, +12 authors, Christopher D Willey.
Cancer Res, 2022 Feb 24; 82(8). PMID: 35195258    Free PMC article.
The Current State of Treatment and Future Directions in Cutaneous Malignant Melanoma.
Madison Ernst, Alessio Giubellino.
Biomedicines, 2022 Apr 24; 10(4). PMID: 35453572    Free PMC article.
Immune checkpoint inhibitors for the treatment of melanoma.
Francesco Sabbatino, Luigi Liguori, Stefano Pepe, Soldano Ferrone.
Expert Opin Biol Ther, 2022 Feb 09; 22(5). PMID: 35130816    Free PMC article.
Pressure increases PD-L1 expression in A549 lung adenocarcinoma cells and causes resistance to anti-ROR1 CAR T cell-mediated cytotoxicity.
Zhenglin Ou, Xiaolin Dou, Neng Tang, Guodong Liu.
Sci Rep, 2022 Apr 29; 12(1). PMID: 35484298    Free PMC article.
Association between plasma somatic copy number variations and response to immunotherapy in patients with programmed death-ligand 1-negative non-small cell lung cancer.
Xiaochen Zhang, Yina Wang, +4 authors, Nong Xu.
J Int Med Res, 2022 Apr 26; 50(4). PMID: 35466753    Free PMC article.
Evaluation of radio-immunotherapy sequence on immunological responses and clinical outcomes in patients with melanoma brain metastases (ELEKTRA).
Jessica C Hassel, Timo E Schank, +13 authors, Philipp Beckhove.
Oncoimmunology, 2022 Apr 29; 11(1). PMID: 35481285    Free PMC article.
Nanoengineering a metal-organic framework for osteosarcoma chemo-immunotherapy by modulating indoleamine-2,3-dioxygenase and myeloid-derived suppressor cells.
Qingxin Fan, Jing Zuo, +4 authors, Qingquan Kong.
J Exp Clin Cancer Res, 2022 May 04; 41(1). PMID: 35501823    Free PMC article.
An Immunity-Associated lncRNA Signature for Predicting Prognosis in Gastric Adenocarcinoma.
Xiaowen Zhao, Pingfan Wu, +8 authors, Yali She.
J Healthc Eng, 2022 May 06; 2022. PMID: 35509706    Free PMC article.
The role of DNA mismatch repair in immunotherapy of human cancer.
Yuchen He, Luyuan Zhang, +2 authors, Hao Chen.
Int J Biol Sci, 2022 May 12; 18(7). PMID: 35541922    Free PMC article.
A novel cancer vaccine for melanoma based on an approved vaccine against measles, mumps, and rubella.
Manlio Fusciello, Erkko Ylösmäki, +8 authors, Vincenzo Cerullo.
Mol Ther Oncolytics, 2022 May 17; 25. PMID: 35572195    Free PMC article.
A review of mechanisms of resistance to immune checkpoint inhibitors and potential strategies for therapy.
Yu Fujiwara, Arjun Mittra, Abdul Rafeh Naqash, Naoko Takebe.
Cancer Drug Resist, 2020 Jun 18; 3(3). PMID: 35582437    Free PMC article.
Resistance mechanisms in melanoma to immuneoncologic therapy with checkpoint inhibitors.
Sarah E Fenton, Jeffrey A Sosman, Sunandana Chandra.
Cancer Drug Resist, 2019 Sep 19; 2(3). PMID: 35582566    Free PMC article.
Necroptosis-associated classification combined with tumor microenvironment characteristic analysis of cutaneous melanoma.
Gang Hu, Yan Jiang, Jianying Ma, Hui Zhan.
Sci Rep, 2022 May 25; 12(1). PMID: 35610275
Analysis of interactions of immune checkpoint inhibitors with antibiotics in cancer therapy.
Yingying Li, Shiyuan Wang, +3 authors, Guohui Li.
Front Med, 2022 Jun 02;. PMID: 35648368